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ABSTRACT 
In most of the cases, patients are diagnosed and treated directly based on the clinical 
laboratory results. Thus the impact of laboratory errors and delays to the patient safety is 
significant, and has drawn increasing attention from both the general public and the 
healthcare professionals. Nowadays, the laboratory error rate is still high and continuously 
results in serious or irreversible medical consequences. It is critical to develop an effective 
and efficient quality system to prevent and reduce the errors and delays, or at least detect 
and correct them before it is too late. 
This study focuses on the risk assessment of patient safety in the entire processes (i.e. pre-
analytical, analytical and post-analytical phases) in a clinical laboratory: Core Molecular 
Biology Laboratory (Core BM) in Hospital Clínic de Barcelona, which was newly-built in 
January 2016. It is a prospective risk assessment that helps to evaluate and improve the 
designed processes before their full implementation, to ensure the laboratory quality as well 
as patient safety ultimately.  
According to ISO standards and guidelines, the processes of the Core BM were assessed 
using Failure Modes and Effects Analysis (FMEA), with the help of Fishbone Cause-Effect 
Diagram. 216 risks were identified, the majority of which were from pre-analytical and 
analytical phases. 21 risks were ranked as high or medium priority to be treated, which 
mainly focused on sample quality and manual procedures. Actions were proposed to 
relevant processes for implementation.  
This is the first study in Europe that applied FMEA in a hospital clinical laboratory in the 
TTP scope, i.e. pre-analytical, analytical and post-analytical phases of Core BM. It has laid 
the foundation of the risk management system in the laboratory, and allows the future 
improvement from both detailed steps and general scope. 
 
Keywords: Risk, Patient Safety, Clinical Laboratory, Analytical Process, FMEA 
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RESUMO 
Na maioria dos casos, os pacientes são diagnosticados e tratados directamente com base em 
resultados clínicos laboratoriais. Assim, o impacto dos erros de laboratório e atrasos sobre 
a segurança do paciente é significativo, e tem atraído cada vez mais atenção tanto do público 
em geral como dos profissionais médicos. Hoje em dia, a taxa de erro de laboratório é ainda 
elevada e resulta continuamente em consequências médicas graves ou irreversíveis. É 
fundamental desenvolver um sistema de qualidade eficaz e eficiente para prevenir e reduzir 
os erros e atrasos, ou pelo menos detectar e corrigi-los antes que seja tarde demais. 
Este estudo centra-se na avaliação de risco da segurança do paciente nos processos 
completos (ou seja fases pré-analítica, analítica e pós-analítica) num laboratório clínico 
recém-inaugurado: o laboratório de Biologia Molecular núcleo (Núcleo BM) no Hospital 
Clínic de Barcelona. O estudo é uma avaliação do risco potencial que ajuda a avaliar e 
melhorar os processos concebidos antes da sua plena aplicação, de forma a garantir a 
qualidade de laboratório, bem como a segurança do paciente, em última instância. 
De acordo com as normas e diretrizes da ISO, os processos do núcleo BM são avaliados 
utilizando o método “Failure Modes and Effects Analysis” (FMEA), com a ajuda de 
diagramas de causa-efeito espinha de peixe. Foram identificados 216 riscos, a maioria das 
quais eram de pré-Analytica e fases de análise. 21 riscos foram classificados como de alto 
ou médio prioridade a ser tratado, que se concentrou principalmente na qualidade da 
amostra e procedimentos manuais. Ações foram propostas para os processos relevantes para 
a implementação. 
Este é o primeiro estudo na Europa, que aplicado FMEA em um laboratório clínico 
hospitalar no âmbito TTP, isto é, as fases pré-analítica, analítica e pós-analítica do núcleo 
BM. Ele lançou as bases do sistema de gestão de risco em laboratório, e permite a melhoria 
futura de ambas as etapas detalhadas e alcance geral. 
 
Palavras chave: Risco, Segurança do Paciente, Laboratório Clínico, Processo 
Analítico, FMEA 
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1 INTRODUCTION 
1.1 Patient Safety in Healthcare Industry 
Among the 10 facts published by WHO in 2014, it is estimated that in developed countries 
as many as 1 in 10 patients is harmed while receiving hospital care [1]. This rate is nowhere 
lower in the European countries: every 10th patient in Europe experiences preventable harm 
or adverse events in hospital, causing suffering and loss for the patient, their families and 
healthcare providers, and taking a high financial toll on healthcare systems [2]. 
The moral imperative that generations of students and doctors have taken to be an ethical 
foundation to their practice – “first do no harm” – is one that is flouted inadvertently or 
deliberately on a daily basis [3]. However nowadays healthcare is not as safe as it should 
be. What goes wrong? According to the Murphy’s Law, whatever can go wrong, will go 
wrong. In the context of healthcare industry, it works the same. And the cost is inevitably 
– patient safety.  
Based on 1984 data developed from reviews of medical records of patients treated in New 
York hospitals, the US Institute of Medicine (now National Academy of Medicine) 
published the famous report: "To Err Is Human: Building a Safer Health System." [4], 
which dropped a bombshell on the healthcare industry by reporting that up to 98,000 
Americans per year die directly as a result of medical errors. The number disclosed that 
medical errors represent one of the leading causes of death and injury in the US [5], 
probably the third one following heart diseases and cancers [6, 7]. The fact was reinforced 
the next year by the UK's “An Organisation with a Memory” [8]. 
Since then, the issues of patient safety and medical errors have become important topics in 
health policy and healthcare practice in several countries. And they are discussed 
ubiquitously in the mass media to continuously draw attention and criticism of the public. 
The healthcare professionals have been making more prospective effort to counteract this 
problem. The US, Australia, UK, Denmark and Canada are among the pioneers to build a 
safer healthcare system for patients by initiating focused efforts to reduce medical errors 
and improve patient safety [9]. 
Despite the worldwide concern of this topic, there is no standard definition of “patient 
safety”. WHO defines “Patient safety is the absence of preventable harm to a patient during 
the process of healthcare. The discipline of patient safety is the coordinated efforts to 
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prevent harm, caused by the process of healthcare itself, from occurring to patients.” [10]. 
Summarizing the similar definitions from the WHO Regional Office for Europe [11], the 
UK National Health Service (NHS) [12], the Agency for Healthcare Research and Quality 
[13], and academic books and literatures [14, 15], the main characteristics of “patient 
safety” are:  
(1) The ultimate goal is to eliminate preventable harm from reaching to the patient;  
(2) Preventable harm is generated during healthcare processes, which include errors that 
deviate from the good medical practise, and preventable accidents during the course of 
healthcare service (e.g. accidental falls);  
(3) Preventable harm may cause physical or mental injury for a patient (from mild to 
severe);  
(4) Errors that could have caused harm to patients should also be considered (potential 
hazard);  
(5) The approach is to prevent, recover and reduce errors and accidents as much as possible; 
(6) Ensuring patient safety is a systematic effort through the processes of delivering care in 
a complex system, not an "individual provider issue".  
Despite the continuous effort made by healthcare professionals, the situation seems to be 
worse. An updated estimate was developed from modern studies published from 2008 to 
2011. The number of premature deaths associated with preventable harm to patients was 
estimated at more than 400,000 per year in the US. Serious harm seemed to be 10- to 20-
fold more common than lethal harm [16]. However, the data revealed is only a tip of an 
iceberg. First, the data is only about deaths, not including other level s of harms. Second, 
the outpatient data is difficult to collect. Third, the studies can only collect the incidents 
that are directly attributed to healthcare process while many lay hide due to lack of clear 
evidence. Fourth, the data is not adequately reported largely as a result of attempting to 
avoid blame. In the UK, it is estimated that only 5% of incidents are adequately reported 
[17].  
While healthcare has become more effective it has also become more complex, with greater 
use of new technologies, medicines and treatments [11]. Admitting the fact that the 
automation, modern technology and better trained staff may have reduced the possibility of 
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errors, patient harm caused by medical errors increased nonetheless. The reasons could be 
complex: 
- Increased complexity of medical practice and operational management 
- Higher expectation vs. more difficult decisions required by aging population and 
complicated diseases 
- Overloaded work with rapider patient flow vs. increasing economic pressure 
- Overuse of risky, invasive, revenue-generating procedures  
- Over-confidence on new technology and procedures 
- Barriers in cross-disciplinary teams communication 
Patient safety is a multifactorial and complex issue that has no one-shot solution. It needs 
all parties’ effort and cooperation. These efforts rely on the patient and his family, the 
healthcare professionals and organizations, in the regulatory and accreditation bodies, 
among suppliers, and at policy levels, including government and non-governmental 
organizations. 
Patient safety is now recognized in many countries, with global awareness fostered by the 
WHO’s World Alliance for Patient Safety. And yet there continue to be significant 
challenges to implementing patient safety policies and practices. However it is worthy of 
accepting these challenges not only for the patient welfare, but also for saving the resources 
and costs for the healthcare industry and the government. European Statistics show that 
strategies to reduce the rate of adverse events in the European Union alone would lead to 
the prevention of more than 750,000 harm-inflicting medical errors per year, leading in turn 
to over 3.2 million fewer days of hospitalization, 260,000 fewer incidents of permanent 
disability, and 95,000 fewer deaths per year [2].  
1.2 Clinical Laboratory and Patient Safety 
Diagnostic errors are an important source of preventable harm [18]. To a large extent, the 
diagnosis for patients depends directly on the clinical laboratory results [19, 20]. Laboratory 
testing is widely used to diagnose disease and disease subtypes, to determine optimum 
treatments and patient’s likely response to a treatment, to make judgment of patient’s 
recovery, etc. Among medical errors, the laboratory errors are the mostly neglected, 
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underestimated, but significant factor which contributes almost 55-58% of diagnostic errors 
[20, 21]. 
Therefore, it is very important to make sure that laboratory services are of high quality – as 
medical decisions made based on them could only be as good as the quality of the results 
supplied. To better control the quality delivered by the clinical laboratory, generations of 
physicians tried to describe the loop of testing process. Thus, a now widely accepted 
concept of “Total Testing Process” (TTP) evolved through the past 40 years. 
The concept was firstly shaped in 1971 aiming to aid the predicted automated clinical 
laboratory testing process [22]. Lundberg developed the idea to the “brain-to-brain 
turnaround time loop”, focusing more on the patient-clinician reaction and the interaction 
with the laboratory test. “A laboratory test begins when a clinician’s brain decides there is 
a need for such a test. It proceeds through a series of steps from that point forward: 
Question, test selection, ordering, identification of patient and specimen, collection, 
transportation, preparation, analysis, reporting, interpretation, and action.” [23]. Sometimes 
the first two steps are integrated to the ordering step since they are in the brain of the 
clinician that will be reflected in the ordering. Schumacher, et al. suggested “patient effect 
follow-up” should be added after action as the final step [24].  
The TTP is a systems-based framework for the evaluation of the interactions, connections, 
and activities involved in the testing process. The process is circular and includes the all 
phases of the testing cycle. Cognitive tasks are required at multiple steps, by both the 
primary care provider and the laboratory [25]. Anything that stands in the way of the 
prompt and perfect receiving of laboratory results for the patients is perceived as a 
"laboratory problem or error." If any inappropriate action occurs within this loop, it will 
cause, at the most, a tragedy and, at the least, a waste [26]. This framework allows the 
design and implementation of interventions that may reduce or eliminate errors that 
adversely affect testing and patient-health outcomes. This framework also allows for the 
study of barriers and limits to quality-improvement activities. The TTP encompasses all 
components or steps of the cycle from the point of the clinical question to the point of 
clinical action [25]. Traditionally it is a cycle consisting of three phases: pre-analytic, 
analytic, and post-analytic phases. Figure 1 shows the TTP adapted from Smith, et al. [25] 
and Plebani, et al. [27]. 
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Figure 1. The Brain-to-Brain Loop of TTP (adapted from [25, 27]) 
The quality of all processes occurring in these phases, associated in a workflow, determine 
the quality of test or results, e.g. accuracy, precision, reliability, turn-around time, etc. 
However, most attention - developmental and strengthening efforts (e.g. quality assurance 
system, new technology, maintenance etc.) - has been focused on the analytic phase. The 
pre-analytic and post-analytic phases, which are also referred to as clinic-laboratory 
interface (CLI), have been largely neglected. Errors are known to occur in any of the phases, 
with majority of the errors being found to occur in the pre-analytic and post-analytic phases. 
The testing processes that are more affected are those that occur outside the laboratory, 
meaning at healthcare facilities. Such processes include: specimen collection, storage of 
specimen, specimen packaging and transportation, completion of test forms, test ordering, 
test result collection and filing, and finally using and acting upon the results for patient 
management and decision making. Some of the errors particular to CLI include 
inappropriate test requests, misidentification of patient, inappropriate test tube, inadequate 
sample collection and transport, inadequate sample/anticoagulant volume ratio, insufficient 
sample, labelling errors, improper data entry, etc. For the provision of high quality 
laboratory services that respond to healthcare needs, it would be necessary to pay attention 
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and strengthen all the phases in laboratory process cycle [28]. With this consideration, this 
study includes all the upstream and downstream workflow of Core BM to assess the risk.  
1.3 Clinical Laboratory Quality Management 
The past decades have seen sustained improvements in analytical performances, such as the 
reduction of the turnaround time (TAT), but the error rate, particularly in pre- and post-
analytical phases is still high [29]. There exist many obstacles to build a clear and quantity-
oriented monitoring system. The lack of a universally accepted methodology and 
“allowable error rate”, the practical difficulty in reporting and measuring the number of 
errors, reduce the possibility of evaluating the impact of laboratory errors on patient safety. 
Bonini, et al. pointed out several major factors: there is a need for better definition of 
laboratory errors and their causes, for classifying laboratory errors by relating them to their 
effects on patient outcomes, and for allowing definition of the relevance of the error itself. 
A standard for laboratory error detection and reporting needs to be defined, and an accurate 
analysis of the risk of errors in the clinical laboratory needs to be performed.  
Among recent independent studies, laboratory error data was collected from worldwide 
healthcare organizations and analyzed. Different error classification systems and safety 
assessment criteria were proposed. Specific risk management guidelines were also 
developed for managing the health risk in clinical laboratory errors [30, 31]. Risk 
management can minimize the chance of errors and ensure reliability of test results in a 
prospective way. It develops various quality control activities employed by the laboratory 
to achieve the goal of generating accurate and reliable test results. 
1.4 Risk Management and Patient Safety 
Compared to the risks in any other industries, healthcare is a relatively high risk area [32] 
and has less tolerability of errors. Medical errors are extremely serious and thus very 
sensitive to the general public. 
ISO/IEC Guide 51:2014 defines “safety” as “freedom from risk which is not tolerable” [33]. 
“ISO15189:2012 Medical laboratories - Requirements for quality and competence” 
requires: “The laboratory shall evaluate the impact of work processes and potential failures 
on examination results as they affect patient safety, and shall modify processes to reduce 
or eliminate the identified risks and document decisions and actions taken.” [34]. To ensure 
patient safety, as a part of clinical laboratory quality management system, risk management 
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for a clinical laboratory is a necessity. It is a valuable tool that can help managers and 
clinical staff improve their work and the care delivered to patient [35].  
Risk management benefits the healthcare industry as it: 
- Strives for the optimal balance of risk by focusing on the reduction or mitigation of risk 
while supporting and fostering innovation so the greatest returns can be achieved with 
acceptable results, costs and risks; 
- Helps healthcare organizations comply with the quality standards and obtain or 
maintain accreditations; 
- Supports better decision-making through a solid understanding of all risks and their 
likely impact; 
- Helps healthcare organizations plan for uncertainty, cope with the impact of unexpected 
events and increase staff, patient and public confidence in care that is delivered with 
well-considered contingency plans; 
- Highlights the weakness and vulnerability in procedures, practices and policy changes. 
 
2 STUDY OBJECTIVES 
This risk assessment study is designed to identify and assess the potential risks that could 
affect patient safety in the Molecular Biology Laboratory (Core BM) and related pre-
analytical and post-analytical areas; to propose improvement actions in order to remove, 
reduce or control the risks; and to lay the foundation of the risk management system for 
Core BM.  
 
3 RATIONALE AND METHODOLOGIES 
According to the ISO31000 [36], the process of risk management is shown in Figure 2. 
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Figure 2. Risk Management Process [36] 
Ideally, risk assessment is performed at the start of a new system design or before its 
implementation. For ongoing systems, a retrospective risk assessment can also be 
performed to make improvements. However, considering the organizational structure and 
heavy workload in the reality of Core BM, the risk assessment is performed in different 
situations:  
(1) For pre-analytical and post-analytical phases, both are functioning according to a well-
established system. Only the interface processes with Core BM are new. However all of the 
processes have impact on the Core BM work flow, and they have never been assessed this 
way. A risk assessment was performed for all the processes in pre-analytical and post-
analytical phases, also considering that almost 80% of laboratory errors originate from these 
less-automated areas [20].  
(2) For the analytical phase, since the Core BM clusters several common functions within 
the CDB, all the working processes are maintained directly from previous functions and are 
implemented immediately. The risk assessment can only be performed while the system is 
functioning. What makes the situation more complicated is: new equipments are under 
testing while the old equipments are still in service; all the equipments are functioning while 
being adjusted frequently; the interfaces with other services are new and not unified. 
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Considering the time limitation, the step of risk treatment, monitoring and review were not 
performed within this study but will be continued in the hospital.  
3.1 ISO Standards of Quality and Risk Management 
The laboratory follows the general principles of “ISO15189:2012 Medical laboratories — 
Requirements for quality and competence” [34]. This study follows “ISO31000:2009 Risk 
management” [36], and “ISO/IEC Guide51:2014, Safety aspects — Guidelines for their 
inclusion in standards” [33]. The terminology used in this study refers to “ISO/IEC 
Guide73:2009 Risk management – Vocabulary - Guidelines for use in standards” [37].  
3.2 Failure Modes and Effects Analysis 
While the whole system related to Core BM is functioning without previous risk 
assessment, a prospective Failure Modes and Effects Analysis (FMEA) is performed. 
Ideally, FMEA begins during the earliest conceptual stages of design and continues 
throughout the life of the system service when changes occur. In the case of Core BM, 
FMEA was performed at the time of transition and trial operation. 
From the ISO/TS223671 definition, FMEA is a systematic review of a system or product 
involving identification of potential failures and assessing the impact on total 
system/product performance of that failure. FMEA was first introduced in US military in 
1960s and developed by the aerospace and automotive industries [38]. It has been adopted 
by the healthcare industry since 1990s. With the requirement of JCHAO [39], now FMEA 
is universally applied in healthcare industry especially in clinical laboratory [40]. This study 
adopts the Clinical and Laboratory Standards Institute (CLSI) guidelines for FMEA [30] 
and customizes the methodology according to the actual situation for Core BM.  
The steps applied in this study are as follows (adapted from the recommendation of 
American Society for Quality [38]: 
1) Assemble a cross-functional team of people with diverse knowledge about the 
organization, process, equipments and customer needs. 
2) Identify the scope and boundaries of the FMEA. It is for the newly-built Core BM and 
all its related processes. It should be as detail as possible to identify every possible error.  
                                                 
1 ISO/TS 22367: 2008. Medical laboratories—reduction of error through risk management and continual improvement 
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3) Break the scope into separate subsystems: pre-analytical, analytical and post-analytical 
phases. Within each subsystem, identify different processes dedicated to diverse 
functions.  
4) For each function, identify all the potential failure modes for every process (how the 
process could go wrong), with the help of process maps. This is a brainstorming step 
that needs to analyze all the factors within each single process and to hypothesize the 
ways they can go wrong.  
5) For each failure mode, identify all the potential consequences on the process, related 
processes, or the delivered outcome (identify all possible “Immediate Effects” in 
regards of process failure or testing result), and finally on patient safety (“End Effects”). 
Determine how serious the “End Effects” is. Severity (S) is rated on a scale from 1 to 5 
(Table 1). If a failure mode has more than one potential “End Effects”, use the highest 
severity score (the worst).  
Table 1. Severity Scoring Criteria 
Severity (S) The potential end effects on lab result output for one run, or directly on patient safety 
Value Significance Definition 
1 
No relevant effect 
on safety 
No effect on patient safety, system operable, history data not well maintained 
2 Minor 
Result acceptable with minor defect or can be corrected easily and immediately, patient 
mental discomfort (confusion, anxiety, distrust, etc.) 
3 Moderate 
Result acceptable with obvious defect, need more effort to correct. E.g. inaccurate or 
incomplete 
4 Critical 
Delayed or unreliable result, unacceptable result or repetition needed, delayed diagnosis/ 
treatment, patient is mal-treated physically, e.g. blood is taken more than necessary 
5 Catastrophic 
Erroneous result that will misleading the diagnosis, no result, or patient safety is directly 
jeopardized. E.g. incorrect or reversed result, patient is treated with wrong approach or 
adverse event is resulted 
6) For each failure mode, determine all the potential causes applying the best knowledge 
and experience of the team. The causes are used to estimate the probability (P), to 
identify the existing detection methods for assigning detectability (D), and finally to 
propose actions. 
7) For each failure mode, determine the probability of its occurrence during the lifetime 
of the scope (considering all the causes that could result in this failure mode). Determine 
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how likely or frequently it is to occur. Probability (P) is rated on a scale from 1 to 5 
(Table 2). The probability can be estimated with the reference of the relevant history 
record, if exists.  
Table 2. Probability Scoring Criteria 
Probability (P) Frequency or likelihood to which extent the failure mode is likely to occur 
Value Significance Definition 
1 Extremely unlikely or Never detected < 1 in 150,000 patients or cases (< 0.0007%) 
2 Remote > 1 in 10,000 patients or cases (0.01%) 
3 Occasional > 1 in 2,000 patients or cases (0.05%) 
4 Reasonably possible > 1 in 200 patients or cases (0.5%) 
5 Frequent > 1 in 20 patients or cases (> 5%) 
8) For each failure mode, identify current methods of detection for all the causes and the 
failure mode itself. These methods might prevent the causes from leading to a failure, 
reduce the probability of occurrence or detect the failure mode after its occurrence but 
before the patient safety is affected. In other words, the detectability defines the 
probability of stopping the failure from leading to the end effect on patient safety. The 
score determines how difficult it is to detect the failure mode or its causes. Detectability 
(D) is rated on a scale from 1 to 5 (Table 3).  
Table 3. Detectability Scoring Criteria 
Detectability (D) 
The possibility of detecting either the failure mode or its cause(s) using current existing 
methods after their occurrence and before the patient safety is affected 
Value Significance Definition 
1 Certain - always detectable 
Current methods are almost certain to detect. Reliable detection 
controls are known with clear process 
2 High High likelihood current methods will detect 
3 Moderate Moderate likelihood current methods will detect 
4 Low Low or remote likelihood current methods will detect 
5 Undetectable - impossible to detect No known methods are effective to detect 
9) Organize team review meetings to review the identified failure modes, effects, causes, 
detection methods, and the rating is given with the agreement of all team members. This 
is a time-consuming step that needs rounds of discussions to reach final agreement.  
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10) Calculate the risk priority number (RPN), which equals S × P × D. These numbers 
provide guidance for ranking potential failures in the order they should be treated. The 
RPN matrix (Table 4) defines the priority of treating the risks.  
Table 4. RPN Matrix 
RPN 
RL   
1 2 3 4 5 6 8 9 10 12 15 16 20 25  RPN 
D
e
te
ct
ab
ili
ty
 1 1 2 3 4 5 6 7 8 10 12 15 16 20 25  Low 
2 2 4 6 8 10 12 16 18 20 24 30 32 40 50  Minor 
3 3 6 9 12 15 18 24 27 30 36 45 48 60 75  Medium 
4 4 8 12 16 20 24 32 36 40 48 60 64 80 100  High 
5 5 10 15 20 25 30 40 45 50 60 75 80 100 125   
11) Propose recommended actions. These actions may be design or process changes to 
lower severity or probability. They may be additional methods to improve detection.  
12) As actions are completed, evaluate new S, P or D ratings and calculate new RPNs. 
Check if improvements are shown after the implementation of the recommended 
actions. 
13) Note: Risk in FMEA is identified by "failure mode". Each "failure mode" can result in 
multiple effects and can have multiple causes. As such, finally multiple actions can be 
proposed to all the causes to eliminate the occurrence of one "failure mode" (one row). 
3.3 Fishbone Cause-Effect Diagram  
The fishbone diagram (Ishikawa Diagram) helps to structure a systematic thinking. It 
identifies all the possible cause categories for a general effect (the loss of a function) and 
helps in FMEA step 6. This study developed the fishbone diagrams with the reference of 
American Society for Quality [41]. They are described for for pre-analytical phase (Figure 
3) analytical phase (Figure 4) and post-analytical phase (Figure 5).
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Figure 3.  Fishbone Diagram for Errors or Delays in the Pre-analytical Phase 
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Figure 4.  Fishbone Diagram for Errors or Delays in the Analytical Phase  
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Figure 5.  Fishbone Diagram for Errors or Delays in the Post-analytical Phase 
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4 RESULTS AND DISCUSSIONS 
4.1 Scope and Boundaries 
This study was applied to the Core BM in the Biomedical Diagnostic Center (CDB) of 
Hospital Clínic de Barcelona. The Core BM was newly-built in January 2016 to centralize 
a series of DNA analysis services that were previously performed separately by individual 
department.  
The CDB comprises all the laboratories of Hospital Clínic de Barcelona. It attends to the 
laboratory needs of 400,000 patients annually from Hospital Clínic de Barcelona and 
receives samples from 80,000 patients seen in other hospital centers and private 
laboratories. Approximately 7,000,000 determinations within 2,327 different tests are 
performed per year [42]. 
To assess the risks, the entire workflow of the Core BM was studied, including pre-
analytical, analytical and post-analytical phases. The CDB laboratory departments studied 
are described in the organization chart in Figure 6.  
 
Figure 6. CDB Organizational Chart 
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General function of each department: 
- Extraction Center Reception (Reception CE): Patient goes to the Reception CE first 
to activate the test request(s) and/or to ask for information. The detailed processes 
are shown in Figure 7. 
- Extraction Center (CE): Patient blood sample is extracted and urine sample is 
collected in CE. The detailed processes are shown in Figure 8 and Figure 9. 
- Reception of Samples (RM): The internal and external samples are received, 
registered, processed and transported to analytical laboratories. The detailed 
processes and its interaction with Secretary UGC are shown in Figure 10. 
- Secretary UGC: For both pre-analytical and post-analytical phases, the internal and 
external incidences and requirements are managed, documents and result reports are 
archived and managed. The detailed processes are shown in Figure 11 and Figure 
12. 
- Core BM Extraction Platform: Samples from RM and other internal and external 
clients are received, registered. DNA is extracted, normalized and quantified.  The 
detailed processes are shown in Figure 13 and Figure 14. 
- Core BM PCR Sanger: From the extracted DNA, the entire PCR Sanger sequencing 
process is performed. The entire processes are shown in Figure 15, Figure 16 and 
Figure 17. 
- Core BM NGS: Currently NGS robot process has not been established. This study 
excludes the NGS process.  
- Core BM Fragment Analysis: It is performed for the DNA samples sent from other 
services. The detailed processes are shown in Figure 17. 
- Other services: Samples of different type can be sent directly from other CDB 
services to Core BM, and are extracted or analysed here. In some cases samples are 
returned to these services per request. The interaction between Core BM and other 
services are generally shown in Figure 13 and Figure 17. 
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4.2 Cross-Functional Team Organization 
The professionals included in the cross-functional team are:  
Pre- and Post-analytical area team: 2 laboratory coordinators, 1 quality unit expert, 1 
facilitator; 
Analytical area (Core BM) team: 2 technicians, 3 laboratory physicians (one of them is 
also the Core BM manager, and another one is the Core BM quality manager), 1 quality 
unit expert, 1 facilitator.  
3 rounds of review meetings were held for reviewing and assessing the risks of pre- and 
post-analytical area; while 6 were held for reviewing and assessing the risks of Core BM.  
4.3 Process Maps 
In this chapter, the process maps for each individual department are described in detail 
(Figure 7 to Figure 17), based on the observational studies and interview with 4 staff in 
Reception CE, 8 staff in CE, 12 staff in RM, 7 staff in Secretary UGC, 7 technicians and 3 
physicians in Core BM.  
General instructions of reading the process maps: 
- Following each process map, a detailed annotation is described for each numbered 
step. The same steps across the departments are not described repeatedly.  
- The dash lined steps are performed by other departments, which interact with the 
department described in the process map.  
- The multi-process steps are either described in a separate process map, or described 
in the following text.  
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4.3.1 Pre-analytical Phase: Reception of Extraction Center 
 
Figure 7. Process Map of Reception CE 
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1. Organize and call patients in the queue: Patients are grouped according to the 
appointment time (every 15 min is one group). Q-Matic displays the current appointment 
group on the screen. Patients who have the appointment of this time queue in front of the 
reception desks and go to the desks one by one. After the completion of one group (about 
15 min), call the next group by pressing the Q-Matic keyboard. 
2. Patient reception: ask patient name: ask the name of the patient, check the consistency 
with the lab test request that the patient brings. If the patient does not bring the request, 
check with the other documents that the patient brings: appointment, DNI (ID card) or TSS 
(Social Health Card).  
3. Ask result or proof? : If the patient comes to fetch his previous test result, print a lab 
report copy as requested. If the patient asks for a proof of attendance or a proof of 
companion, prepare accordingly and stamp it.  
4. Functional tests? :  If the patient comes to schedule his functional tests, desk 4 staff 
should program the schedule in the excel “IMP-812 Functional Tests Agenda” and 
manually complete the “IMP-821 Functional Tests Appointment Sheet” and give to the 
patient.  
5. Activate request in SIL OK? : If the patient comes with a request to give samples, 
activate the request in SIL by scanning the barcode of request number. Manage incidence 
if it occurs. 
6. Find in SAP? : When the patient does not bring his request or request cannot be activated 
in SIL, search in SAP to find the correct request. 
7. Multiple requests? : Patient may come with more than one request. There are different 
tests on different requests.  
8. Combine requests: Activate each request and select “combine” in SIL. SIL 
automatically adopts the number of the oldest request. By doing so, all the tests have the 
same request number.  
9. Print labels and give to patient: After the activation of all requests for one patient, print 
all the test labels and give them to the patient.  
10. 24h urine sample and label consistent? : When there is a label for “24h urine”, if the 
patient does not bring the sample, create a new request for the test “24h urine” in SIL so 
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that the patient can bring the sample next time. If patient brings the sample or there is no 
label for “24h urine”, patient can leave for extraction directly. 
11. Assign SGC category and nº of extraction: According to the information given by the 
patient himself or from the request, assign SGC category (Normal, Urgent, Port-a-cath, 
Sintrom, Wheelchair, Histocompatibility, Myelography) and nº of extraction and give the 
ticket to the patient.  
12. Call patient for re-appointment: If a re-extraction request email from the coordinator 
is received, call the patient and make a new appointment for extraction. The email contains 
all information such as patient name, old request number, test name, reason for re-
extraction, etc.  
13. Create new request: Register in SIL the repeated tests and complete manually “General 
Analytical Request Form”, only for the “24h urine” and other repeated tests. In the case of 
“24h urine” (patient is present without 24h urine sample), patient should bring the new 
request form together with the sample in his next visit. In the case of phone call re-
extraction, archive the new request form and activate when patient comes for re-extraction. 
14. Archive requests: When patient leaves for extraction, archive the requests activated. In 
the case of phone call re-extraction, archive the printed email together with the manual 
request form for patient’s next visit.  
15. Manage incidences: Try to solve the incidence immediately. When nonconformity 
occurs, register in “IMP-823 Resolution of incidences”. 
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4.3.2 Pre-analytical Phase: Extraction Center 
 
Figure 8. Process Map of CE 
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4. Confirm patient name and assign labels to sample containers: Extractor asks the patient 
name and checks with the name on the label(s).  The header label is pasted on “IMP-825 
Registration of Patients Attended to Each Box”, and then the sample labels are assigned to 
corresponding types of containers (tube, syringe, etc.). 
5. Nonconformity? : If nonconformity occurs, extractor should manage accordingly. Ask 
help from coordinator if necessary, register in “IMP-036 Registration of Incidences”. 
6. Blood extraction with proper approaches: Extractor selects proper materials and 
approaches to extract blood samples.  
7. Store sample temporarily: Extractor places the samples under required conditions 
(special conditions include 37ºC incubating, in ice water, light-protected container, etc.) 
until RM staff collects them. 
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Figure 9. Process Map of CE (Reception of Urine) 
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4.3.3 Pre-analytical Phase: Reception of Samples 
 
Figure 10. Process Map of RM 
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4. Activate/ introduce requests in SIL and print labels: Activate the requests in SIL by 
scanning request barcode. For non-standard external requests, introduce all the information 
manually (client, patient and test information). Print labels for all the samples. Archive the 
requests in different categories and send to UGC. 
5. Identify samples: Match and paste the labels with the corresponding sample containers.  
6. Register the traceability and prepare for distribution: For the samples transported from 
CE, scan for “entry” and “exit” in separate computers. For samples received at the reception 
desks (from the internal wards, services or external clients), scan for “exit” only. Distribute 
the samples according to first destinations depending on the destination code on the labels: 
stay for pretreatment (centrifuge, aliquot), send directly to services, send to core lab chain, 
etc. Register diuresis result (“IMP-810 Diuresis Sheet” received from Urine Reception) in 
SIL in a separate computer.  
7. Aliquot? : Some blood or urine samples need multiple aliquots for different tests. Urine 
samples are aliquoted manually; blood samples are normally aliquoted by robot that is 
connected to SIL and assigns labels to aliquots automatically. For insufficient blood 
samples, technicians do manual aliquoting and assign labels manually.  
8. Sample distribution: According to the scheduled timetable and by batch, send the 
samples to services for testing via different pathways. E.g. samples for MIC, IMM should 
be sent by pneumatic pipe; samples for IBC or external labs are fetched by particular 
express companies; some samples must be sent by staff manually. During transportation, 
the required storage condition should be respected. 
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4.3.4 Pre-analytical and Post-analytical Phase: Secretary UGC 
 
Figure 11. Process Map of Secretary UGC (Pre-analytical Phase) 
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manages and registers incidences in “IMP-036 Registration of Incidences”, and returns to 
RM after incidence is solved.  
3. Return samples? : In case of incidence is not solved, ask client if sample(s) should be 
returned. If yes, prepare transportation documents “IMP-811 Sample Return Card” and 
“IMP-817 Registration of Sample Return”. If not, destroy the samples.  
4. Review and correct requests in SIL: All the requests manually introduced by RM or 
Secretary should be reviewed another time. Check all the information on the original 
requests against the introduced information in SIL, correct errors once detected.  
5. Scan requests: All the requests received should be scanned and uploaded to SIL. Check 
if the automatic reading of the request number is correct. If not, correct manually. Once the 
request number is correctly identified, the scanned file is uploaded to corresponding SIL 
request automatically. 
6. Register request origin and quantity: At the end of the day, record in “IMP-802 Reception 
of Requests” the number of requests received daily according to the origin (e.g. external 
clients, wards, scholarships and studies, etc.). Archive the requests.  
7. Add/ delete tests in SIL: Doctor calls Secretary to add or delete tests for the samples that 
are already in processing in the lab. Secretary checks the possibility of adding or deleting, 
and then accept or reject the request. The newly added test is registered directly in SIL 
under the ongoing samples and also on a paper form “IMP-815 Register Modification of 
Request”. 
1. Multiple requests: When RM receives more than 3 requests from one origin, RM keeps 
the samples in pending boxes and leaves the requests for secretary to introduce to SIL. 
Secretary returns labels to RM.  
2. Requests/ samples with incidences: When there are incidences for any request or 
sample that RM receives, RM leaves the sample and request for secretary management. 
Secretary manages and registers incidences in “IMP-036 Registration of Incidences”, and 
returns to RM after incidence is solved.  
3. Return samples? : In case of incidence is not solved, ask client if sample(s) should be 
returned. If yes, prepare transportation documents “IMP-811 Sample Return Card” and 
“IMP-817 Registration of Sample Return”. If not, destroy the samples.  
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4. Review and correct requests in SIL: All the requests manually introduced by RM or 
Secretary should be reviewed another time. Check all the information on the original 
requests against the introduced information in SIL, correct errors once detected.  
5. Scan requests: All the requests received should be scanned and uploaded to SIL. Check 
if the automatic reading of the request number is correct. If not, correct manually. Once 
the request number is correctly identified, the scanned file is uploaded to corresponding 
SIL request automatically. 
6. Register request origin and quantity: At the end of the day, record in “IMP-802 
Reception of Requests” the number of requests received daily according to the origin (e.g. 
external clients, wards, scholarships and studies, etc.). Archive the requests.  
7. Add/ delete tests in SIL: Doctor calls Secretary to add or delete tests for the samples that 
are already in processing in the lab. Secretary checks the possibility of adding or deleting, 
and then accept or reject the request. The newly added test is registered directly in SIL 
under the ongoing samples and also on a paper form “IMP-815 Register Modification of 
Request”. 
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Figure 12. Process Map of Secretary UGC (Post-analytical Phase) 
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4. Check pending list: After calculating the duration against TAT, always check the pending 
list in each client file. Make sure all tests beyond TAT are well traced.  
5. Client claims: Receive claims from internal or external clients via email, telephone or 
other channels, register & manage incidences in “IMP-036 Registration of Incidences” 
database. Update or close the incidence after a new action is taken for a specific incidence.  
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4.3.5 Analytical Phase: Extraction Platform 
 
Figure 13. Process Map of Extraction Platform 
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or from external labs. Some samples should be transported manually by RM staff due to 
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special requirements of storage. The sample types include: blood, amniotic fluid, biopsy 
tissue, dried blood spot, inactivated virus, and DNA or RNA2 samples.  
2. Register & print secondary label in SIL: Technicians scan the primary samples to register 
sample reception in SIL, in the meantime all the secondary labels (for DNA extracted or 
necessary aliquots) are automatically printed. Technicians store the samples in the fridge 
by category depending on sample types or extraction methods. The secondary labels are 
kept in a particular box until they are pasted in an empty eppendorf which is used for 
receiving the final product (normally DNA) or prepared aliquots.  
3. SIL worklist: Technicians print the worklist from SIL to obtain the list of samples that 
are planned to be processed. 
4. Sample and worklist coincide?: Technicians check the consistency between samples 
received and worklist. In case of inconsistent sample number or identity, register and 
manage incidence by contacting different services.  
5. Manual extraction?: For the insufficient blood, amniotic fluid, inactivated virus samples, 
manual extraction will be performed using different protocols. 
6. Pretreatment?: For the dried blood spot, biopsy tissue samples, pretreatment is necessary 
before automatic extraction. E.g. dried blood spot sample needs to be dissolved in liquid 
for automatic extraction; tissues should be treated with cell lysis reagents in advance.   
7. Automatic extraction: In the case of sufficient blood samples or other samples after 
pretreatment, samples can be loaded to automatic extractors depending on sample type. 
MagNA Pure 96 (Roche) is for batch DNA extraction of blood samples (Robot 0 is used 
for sample transfer before and after MagNA Pure 96 processing); MagNA Pure Compact 
(Roche) is for a small quantity of samples and normally used for dried blood spot and 
amniotic fluid extraction. For both extractors, it is necessary to load the empty receiving 
eppendorfs with secondary labels.  
8. QC OK?: DNA samples are quantified with spectrophotometer Nanodrop to test 
concentration and purity; DNA extracted from amniotic fluid should be examined with 
electrophoresis. The QC results are registered in notebook as well as in PC. In case of QC 
                                                 
2 In the process map, all RNA samples are omitted due to the little amount of request every year, and all RNA samples 
are managed manually with special kits 
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not pass, repeat QC to confirm. If the DNA quality is not good, re-extraction should be 
performed for the specific sample.  
9. Sample for Core BM?: Technicians read destination code in the secondary label to 
identify the next stop of the extracted DNA – stay in Core BM for sequencing or fragment 
analysis, or send to services for other tests.  
10. Store & transport sample: Technicians pack the samples (sometimes together with QC 
reports) according to the destinations. Depending on the destinations, technicians send 
samples via pneumatic pipe or store them in the fridge temporarily, waiting for RM staff 
manual transportation.  
11. Quantification and/ or normalization?: All the DNA samples (including received DNA 
samples) that stay in Core BM for sequencing or fragment analysis should be quantified 
and normalized in Robot 1. In case of insufficient DNA (10ul needed for quantification & 
normalization) or special conditions, DNA samples will be loaded in Robot 1 only for 
being transferred to 2D tubes, registration or aliquoting. 
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4.3.6 Analytical Phase: Robot 1 Normalization and Quantification 
Robot 1 quantifies and normalizes the extracted DNA in a 2D tube, which goes to Robot 2 
for PCR assembly.  
 
Figure 14. Process Map of Robot 1 
1. Load samples, sex primers, reagents, extra aliquot tubes: Load DNA samples with 
barcoded labels, place in correct positions the 2 prepared primers for sex PCR QC, water 
and TAQ enzyme. Load PCR plate and empty 2D tubes of Sanger (yellow capped tube with 
a unique 2D code on the bottom) and NGS (red capped tube with a unique 2D code on the 
bottom, not applied yet). Load extra tubes with correct labels for aliquoting DNA.  
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2. SIL data: Robot 1 scans barcode3 of the DNA samples, and reads from SIL the patient 
information (sex, Sanger or NGS sequencing). 
3. Set and check parameters: Technicians manually select the script to run, either 
“normalization” or “registration samples only”, check or enter the “starting position of 
dilution plate”, “starting position of 2D tubes” (this is automatically set according to the 
previous run, but should be checked because after a run of “register & transfer”, the position 
is random), “Do sex PCR QC or Not?). 
4. Automatic quantification: Robot 1 automatically measures the concentration of each 
DNA sample.  
5. Decap 2D tubes as Robot indicates: Before transferring samples to 2D tubes, Robot 1 
asks technicians to manually decap a certain number of 2D tubes. After they are decapped, 
normalization process can be continued.  
6. Automatic normalization: Using the quantification data, Robot 1 automatically calculate 
and dilute the samples into 50 ng/ul in 100 ul in 2D tubes. Each 2D tube is scanned and 
linked with a specific SIL barcode, which both identify the unique sample.  
7. Send data to SIL: After normalization, Robot 1 sends information to SIL automatically 
indicating that the normalization is completed “Completed|date|time”.  
8. Assemble sex PCR: Using 2 primers, Robot 1 automatically assembles PCR reaction for 
each sample in a PCR 96-well plate.  
9. QIAxcel electrophoresis: The sex PCR products are examined in QIAxcel 
electrophoresis automatically. A blank reference is added automatically.  
10. XX, XY results OK? : The electrophoresis result with 1 band indicates the existence of 
XX chromosomes (female), while with 2 bands indicates XY chromosomes (male). In case 
of no PCR products are amplified or poorly amplified, repeat the sex PCR.  
11. Coincide? : Compare the sex PCR results with the sex report generated from SIL (in 
Robot 1). If the results do not coincide, find the causes and resolution. This process is only 
                                                 
3 In Robot 1, barcode of request/ patient is linked with 2D code by Robot 1 programming, and this information is stored 
in robot DB and is used all through the following processes in Core BM 
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to avoid large amount of sample contamination or cross-mixing. In case of cross-mixing 
the samples of the same sex, it cannot be detected.  
12. Archive samples: The primary blood samples are archived for 3 months in Core BM. 
DNA mother samples are kept for 1 week in case repetition is needed, then send to original 
services. The amniotic fluid, dried blood spot and tissue samples are all consumed during 
the extraction.  
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4.3.7 Analytical Phase: Robot 2 PCR Assembly and PCR 
Robot 2 assembles PCR of normalized DNA in 96-well plate, which goes to PCR.  
 
Figure 15. Process Map of Robot 2 
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1. Manual PCR assembly: This is mainly for MIC virus samples, new primer testing and 
for PCR repetition, due to the necessity of special protocols, more delicate operations, or 
small number of samples.  
2. Load reagents and materials: The reagents include 4 tubes of water, 4 tubes of 
AmplitaqGold; the materials include PCR plate, tips, etc. They should be loaded to 
particular positions in Robot 2.  
3. Select script to distribute 2D tubes to different rack: There are 3 racks to receive 2D 
tubes, “GO”, “WAIT” and “END”. 
4. SIL data: Robot 2 asks SIL about the gene(s) to be amplified for each 2D tube according 
to the DNA sample identity. After samples are registered in SIL, lab physicians check their 
own worklist and select exons for the requested gene tests. If such exons information exists 
in SIL, the 2D tube is transferred to “GO” rack to proceed with the PCR assembly; if no 
information exists in SIL (lab physician has not decided), the 2D tube is transferred to 
“WAIT” rack and will be loaded again in the next batch; if the test request is closed or 
canceled by clinical doctors, the 2D tube is transferred to “END” rack and is thrown away 
after this run.  
5. SQL database: For the “GO” samples, Robot 2 asks SQL database what primer(s) will 
be used for each gene amplification. SQL database corresponds SIL data (request#, gene, 
exon, cost center) with primer data to match the sample identity with primer position in 
Cytomat. 
6. Select primers from Cytomat: Cytomat outputs selected primers to the primer rack.  
7. Decap 2D tubes (samples & primers) as Robot indicates: Before assembling PCR 
reaction, Robot 2 asks technicians to decap the “GO” samples and selected primers 
manually.  
8. Assemble in PCR plate and return primers: Robot 2 assembles PCR reaction for each 
exon amplification. Several gene tests can be ordered for one sample (2ul DNA sample is 
necessary for each amplification). There are 5 wells in the PCR plate that are programmed 
to be blank control (no sample is transferred to these wells). After assembly completion, 
primer tubes are scanned and returned to Cytomat.  
9. Send data to SIL: After the completion of PCR assembly, Robot 2 sends information to 
SIL indicating the PCR assembly process is completed “Completed|date|time”.  
 47 
 
10. Seal and identify the PCR plate: Seal and mark the PCR plate with the date, sample 
numbers, plate sequence of the year for easy identification. 
11. PCR: Place the PCR plate in thermocyclers, select appropriate programs of PCR.  
12. Transfer & dilute PCR products in Robot 3 (QIAxcel script): Load amplified PCR plate 
in Robot 3, run “QIAxcel” script to transfer a certain volume and dilute the products into a 
new plate for electrophoresis.  
13. QIAxcel electrophoresis: Load the new plate of diluted PCR products in QIAxcel and 
check if there are amplified products.  
14. Register in SIL & Repeat PCR: In case of PCR failure, register in SIL the failure 
information (i.e. sample ID, which genes are to be repeated), and repeat PCR assembly for 
that sample, manually or automatically.  
15. Return “GO” 2D tube: If the amplification is good, return the “GO” 2D tubes to 
“WAIT” rack in case of test repetition or other request. The PCR products are loaded in 
Robot 3 for purification. 
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4.3.8 Analytical Phase: Robot 3 PCR Purification 
Robot 3 purifies the PCR products and prepares for SEQ or AF reactions. 
 
Figure 16. Process Map of Robot 3 
1. Load PCR plate, Exostar plate, reagent (Exostar): If the QIAxcel QC result shows good 
amplification, PCR products can be loaded in Robot 3 for purification. Load a new plate 
and Exostar reagent to assemble another PCR reaction.  
2. Robot 3 “Exostar” script: Run “Exostar” script. Robot 3 transfers 5ul amplified PCR 
products and prepared “Exostar” 2ul to a new plate “Exostar”.  
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3. PCR “Exostar” program: Seal the Exostar plate and load in thermocycler, run a special 
PCR program “Exostar” to amplify for 5 min. 
4. Load “Bigdye” reagents, new plate (if necessary): Load water, “Bigdye” buffer, 
“Bigdye”, primer M13 Forward (F) and M13 Reverse (R) in appropriate positions.  
5. Robot 3 “Bigdye”script: Run “Bigdye” script. Robot 3 first makes two F and two R 
Bigdye buffer mixes, and then transfers them into new wells. Robot 3 asks technicians to 
enter the number of samples. If sample number <=48 (half of the 96-well plate), the 
“Bigdye” process will transfer half volume of all the Exostar PCR products (3.5ul) to the 
other empty half of the Exostar plate. If sample number >48, a new plate should be loaded 
to receive the transferred samples. All the samples are splitted to 2 parts to prepare for the 
F and R reactions respectively. Robot 3 then mixes F/R Bigdye buffer with samples in each 
plate. At the end of this process, there are 1 or 2 “Bigdye” plate(s).  
6. Load “Edgebio” plate on a new plate: place the “Edgebio” filter gel plate(s) on top of a 
new plate(s) to receive final samples.  
7. Robot 3 “Edgebio” script: Robot 3 transfers all samples in “Bigdye” plate(s) to go 
through the gel. Technicians collect the final plate(s), cover well and centrifuge. 
8. Robot 3 “Formamide” script: Run script “Formamide” to mix with the samples. The 
samples could be the final samples after centrifuge from Robot 3, or the received DNA 
samples for Sanger sequencing from external services. The formamide DNAs are ready to 
be loaded in sequencers. 
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4.3.9 Analytical Phase: Sanger Sequencing and Fragment Analysis 
 
Figure 17. Process Map of Sanger SEQ and AF 
1. External DNA samples: Core BM sometimes receives DNA samples that are already well 
prepared for sequencing or fragment analysis. They are amplified PCR products with 
buffers added. They can be in individual Eppendorfs or in 96-well plates. 
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3. Coincide? : Technicians check the consistency between the samples received and the 
request form. This includes the sample number and sample names. Normally sample names 
are hand-written on each Eppendorfs received, but not on the plate received. On the request 
form there are always the complete information such as request #, sample number, all the 
sample names and their programmed positions, requested test,  responsible lab physicians, 
necessary kits and standards (for fragment analysis). 
4. Transfer samples to 96-well plate (if necessary): Technicians transfer the samples in 
Eppendorfs to a plate according to the programmed positions on the request form. 
Sometimes when combining different requests in one plate to do sequencing in one batch, 
technicians need to re-program the positions manually. If samples come in plates, there is 
no need to transfer. 
5. Register additional information: Register plate name and other additional information on 
the request form and mark the plate with plate ID (e.g. F16 means the 16th sequencing plate 
of the year, F27 means the 27th fragment analysis plate of the year) and date/ time. 
6. Load samples in sequencer: Core BM has 2 sequencers for sequencing and 2 for fragment 
analysis. All of them are with different capacity and can back up for each other. 
7. Worklist: There are different ways to obtain the worklist, depending on the previous 
processing of samples. Robot 3 can automatically output the worklist after processing the 
purification, which can be modified if other samples are manually added to that plate. 
Worklist can be copied from SIL electronic request form directly, if a batch of samples is 
prepared by external services. Also, worklist can be created manually using the particular 
template for each sequencer. 
8. Set parameters: Technicians copy the worklist to the sequencer via a flash disk, enter 
project name, sample names, select standard, folder, protocol, etc., and run. 
9. QC OK?: Technicians check the result quality to make sure the sequencer runs OK, the 
standards are normal, the blank controls have no DNA sequence, and the result for each 
gene of each sample is clear and not mixed. 
10. Automatically distribute results to physician’s folder: Sequencing results for the 
samples that are registered in Robot database can be automatically distributed to responsible 
lab physician’s online folder according to the naming rule. 
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11. Copy & paste results to physician’s folder or email physician: Other sequencing results 
should be copied manually to physician’s folder or sent by email. All the fragment analysis 
results must be sent manually by technicians because currently all the fragment analysis is 
for external DNA samples (not registered in Robot database). 
4.4 FMEA Tables 
The FMEA study was based on the process maps and detailed steps. The “failure modes” 
were identified and are listed in FMEA tables (Table 5 to Table 17). 
General instruction of FMEA tables: 
Step of Process: The steps that bear potential risks. The steps in this column is more 
general and may include several detailed steps in the process maps in section 0 Process 
Maps.  
Failure Mode: It describes how the failure event could occur within a certain step (risk 
description).  
Immediate Effects: All the possible internal effects that would appear immediately after 
the failure occurs and before reaching to the patient. These can be the effects on the 
following processes and/or on the test results. In some cases when the patient is physically 
involved in the step, the immediate effects can impact patient safety directly.  
End Effects: This column only lists the possible effect(s) that could reach to the patient, 
i.e. the effects on patient safety. The Severity score is evaluated based on the worst effect 
on patient safety.  
Causes: This column lists all possible causes for a certain failure mode. The sources of the 
causes can vary from the CDB internal departments, the HCB departments or the external 
clients or organizations. These are the main reference of proposing the actions to treat the 
risk. The probability is evaluated partially based on the sources of the causes (as well as 
the available reference data and professional experiences).  
Methods of Detection:  This column lists the current methods of detecting either the 
causes (to prevent) or the failure mode (to correct) before the patient safety is affected. 
The detection can be done either immediately within the current step or in the following 
steps before the result is delivered to the patient.  
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Column “S”, “P”, “D”, and “RPN”: See section 3.2 Failure Modes and Effects Analysis 
(FMEA). The color of RPN score represents the priority of treating the risk.  
Action Recommended: These are the proposed actions to treat the risks, i.e. to mitigate 
the severity, to decrease the probability, and to setup more effective methods and prevent 
the risk from occurring or reaching to the patient.  
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4.4.1 Pre-analytical Phase: General 
Table 5. FMEA: General 
Pre-analytical: General                     
Step of Process Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RPN Action Recommended 
General 
Patient accidents (e.g. falling, 
unconsciousness, etc.) before 
being extracted 
Patient jeopardized 
Patient adverse 
event 
Accidents Undetectable 5 3 5 75 
First-aid medication in 
place; First-aid training for 
all staff especially those in 
direct contact with patients 
General No electricity 
1-All electronic devices 
stop working 
2-All processes delayed 
Delayed result 
Accident with 
electricity supply; 
Hardware error 
CDB staff observation 4 1 1 4 
Prepare back-up plan for 
electronic processes and 
maneuver to train staff 
General 
SIL does not work or works 
slowly 
All CDB sample 
management processed 
delayed 
Delayed result Software malfunction 
CDB staff observation; 
Regular maintenance 
4 1 1 4 
IT staff regular check and 
solve incidences reported 
(out of SIL working time 
window) 
General PC does not work 
Short delayed processed 
(back-up PC is used) 
No effect 
Hardware 
malfunction 
CDB staff observation; 
Regular maintenance 
1 2 1 2 No 
General Printer does not work 
Short delayed printing 
(back-up printer is used 
or wait for recovering) 
No effect 
Hardware 
malfunction 
CDB staff observation; 
Regular maintenance 
1 2 1 2 No 
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4.4.2 Pre-analytical Phase: Reception of Extraction Center 
Table 6. FMEA of Reception CE 
Reception CE                   
Step of Process Failure Mode Immediate Effects End effects Causes 
Methods of 
Detection 
S P D RPN Action Recommended 
Patient reception 
Patient uses other's Health Insurance Card 
(TSS) as the only identification intentionally 
Request activated 
for another patient 
Result assigned 
to incorrect 
patient 
Patient error Undetectable  5 1 5 25 
Use DNI+TSS double check 
(DNI has photo) 
Patient reception 
Patient uses other's Health Insurance Card 
(TSS) as the only identification 
unintentionally 
TSS rejected (other 
ID documents are 
used) 
No effect Patient error 
Reception staff 
inspection 
1 1 1 1 No 
Patient reception 
The name on request or appointment 
doesn't match with the present patient 
1-Request activated 
for another patient 
2-Request rejected 
1-Misleading 
result 
2-No result 
HCB administrative 
staff error (request or 
appointment 
distribution error) 
Reception staff 
inspection;  
Extractor inspection 
5 3 1 15 
Double confirm patient 
name when distributing 
request or appointment 
Patient reception 
The Q-Matic screen or ticket-printer does 
not function 
Short delayed 
reception 
No effect 
Hardware 
malfunction  
CDB staff 
observation 
1 2 1 2 
Prepare back-up plan for 
queuing process and 
maneuver to train staff 
Patient reception 
Patient has conflicting appointment time for 
blood extraction and doctor consultation 
Short delayed 
reception 
Slight patient 
discomfort 
HCB administrative 
staff error 
(programming 
request without 
checking previous 
schedule) 
Reception staff 
inspection;  
Patient complaints 
2 2 2 8 
Program requests and 
appointments in one 
system to avoid overlap (or 
very close) schedule 
automatically (by system 
alert) 
Patient reception 
Patient goes directly to extraction cubicles 
without activating request 
Short delayed 
request activation  
No effect 
Patient error;  
No clear guidance 
CDB staff 
observation;  
Patient demands 
1 3 1 3 
Give clear instruction on 
the request;  Put clear signs 
and instructions in 
reception area 
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Table 6. FMEA of Reception CE (Continued) 
Reception CE                   
Step of Process Failure Mode 
Immediate 
Effects 
End effects Causes 
Methods of 
Detection 
S P D RPN Action Recommended 
Patient reception 
Patient comes with a closed or 
already activated request 
Request rejected; 
A new request 
generated 
Slight patient 
discomfort 
Doctor or HCB 
administrative staff error; 
Patient error 
Reception staff 
inspection 
2 4 1 8 
Setup alert for doctors when closing 
the request in SAP and always inform 
patient of the change. Reception staff 
always retrieve the activated request 
from patient 
Request order 
Test ordered is incorrect for the 
patient (e.g. a newborn test is 
ordered for an adult) 
Inappropriate test 
performed 
No result (for 
expected test) 
Doctor error (ordering 
incorrect test) 
Extractor inspection 4 3 1 12 
SAP categorizes test by sample type 
and sets automatic check to avoid 
mistake in test selection 
Request order 
Sample type ordered is 
impossible to obtain in the 
extraction center 
Test not 
performed 
No result 
Doctor error (ordering 
incorrect type of sample, 
e.g. body fluids, etc.) 
Extractor inspection 4 3 1 12 
SAP categorizes test  by sample type 
and sets automatic check to avoid 
mistake in test selection 
Request 
activation 
SAP request is not in SIL 
Short delayed 
request activation 
No effect 
Informatics network 
malfunction 
Reception staff 
inspection 
1 3 1 3 No 
Request 
activation 
Another inappropriate request is 
activated (when patient has 
more than 1 appointed requests 
in SIL) 
Inappropriate test 
performed 
No result (for 
expected test) 
Patient error (patient 
comes with a request that 
is programed for a 
different appointment); 
Reception staff error 
Reception staff 
inspection 
3 2 2 12 
Display date/time on request for 
patient and staff to check; Program 
automatic check of the request 
date/time 
Request 
activation 
Requests are manually merged 
incorrectly or the merge is 
incomplete 
Test not 
performed 
No result Reception staff error 
Secretary staff 
review and 
inspection 
4 1 3 12 
Doctor add tests in existing request if 
possible to avoid creating a new 
request; double check after merging 
Label 
management 
Not all labels are given to patient 
Test not 
performed 
No result Reception staff error 
Coordinator checks 
report of "Not 
Received" samples 
in SIL 
4 1 3 12 
Reception staff check the number of 
labels after printing 
Label 
management 
Another patient's labels are given 
to a patient 
Sample 
incorrectly 
identified 
Misleading result Reception staff error 
Patient demands; 
Extractor 
inspection;  
Urine Reception 
staff inspection 
5 2 1 10 Reception staff double check labels 
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Table 6. FMEA of Reception CE (Continued) 
Reception CE                   
Step of Process Failure Mode Immediate Effects End effects Causes 
Methods of 
Detection  
S P D RPN Action Recommended 
Label 
management 
Patient loses the label(s) before 
extraction 
Test not performed No result Patient error 
Coordinator 
checks report of 
"Not Received" 
samples in SIL 
4 3 1 12 
Program and print 
sequence number and 
total number of labels on 
each label (e.g. 1/3, 2/3, 
3/3) for better check 
Label 
management 
Material supply of blank labels is 
used up 
Short delayed label 
printing 
No effect 
Supplier incident;  
Reception staff error (miss 
to order) 
Reception staff 
observation 
1 2 1 2 No 
Extraction priority 
or category 
classification 
Patient (with a special condition) is 
assigned an incorrect extraction 
category ticket (e.g. port-a-cath, 
urgent) 
Short delayed 
extraction 
Slight patient discomfort 
Reception staff error (fail 
to identify the priority, 
print the ticket by error, 
deliver the ticket by error); 
Patient error (not 
communicates the special 
needs) 
Extractor 
inspection;  
Patient demands 
special extraction 
2 4 1 8 
Information of special 
patient is highlighted in 
SIL; always ask patients for 
prioritized types; not share 
ticket-printer; differentiate 
the frequently-pressed 
button (by color, shape…) 
Functional test 
programming 
Incorrect date/ time is registered in 
the programming excel or in the 
patient appointment sheet 
1-Re-appointment 
2-Short delayed 
extraction 
1-Delayed result 
2-No effect 
Reception staff error 
Reception staff 
inspection 
4 2 2 16 
Develop a printable system 
to program instead of 
manual programming in 
excel 
Extraction re-
programming 
Patient is not informed about a 
new extraction that has to be 
performed 
Re-extraction not 
performed 
No result 
Reception staff error (not 
proceed with new 
extraction request) 
Undetectable 4 1 5 20 
Fixed schedule for 
coordinator (email sender)  
and reception staff 
(counter 4) to manage re-
extraction request and 
other special cases; Create 
an alert function in SIL to 
remind of pending re-
extraction request 
Result printing  
Result report of another patient is 
given 
Report incorrectly 
distributed 
1-Non-compliance of 
Personal Data Protection 
Law (LOPD: Ley Orgánica 
de Protección de Datos 
de Carácter Personal) 
2-Delayed result obtain 
Reception staff error 
Patient 
observation; 
External doctor 
inspection 
5 1 2 10 
Staff double-check the 
identity after printing 
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4.4.3 Pre-analytical Phase: Extraction Center 
Table 7. FMEA of CE 
Extraction Center (CE)                     
Step of Process Failure Mode Immediate Effects End effects Causes 
Methods of 
Detection  
S P D RPN Action Recommended 
Q-Matic management Q-Matic does not work 
1-No SGC category for 
patient 
2-Short delayed reception 
and extraction (manual 
organization of queuing) 
Slight patient 
discomfort 
Software malfunction 
CDB staff 
observation 
2 2 1 4 
Prepare back-up plan 
for queuing process 
and maneuver to train 
staff 
Q-Matic management 
Q-Matic is shut down by mistake during 
working time 
Disorder of reception and 
extraction 
Slight patient 
discomfort 
CDB coordinator error 
(lack of control) 
CDB staff 
observation 
2 1 1 2 
Software automatically 
double-confirm, or 
password control 
Q-Matic management 
Q-Matic is operated by unauthorized 
people 
Disorder of reception and 
extraction 
Slight patient 
discomfort 
CDB coordinator error 
(lack of control) 
Coordinator 
observation 
2 1 2 4 
Password control while 
coordinator leaves 
Q-Matic management 
Extraction priority is assigned to an inactive 
cubicle; or different categories with the 
same priority are assigned to a cubicle  
Short delayed extraction No effect CDB coordinator error 
Coordinator 
inspection 
1 3 1 3 
Software automatically 
deactivate the inactive 
cubicle 
Q-Matic management 
Extractor leaves the cubicle without closing 
it off in Q-Matic system 
Short delayed extraction No effect Extractor error 
Coordinator 
inspection 
1 5 1 5 
Better instruction to 
extractor 
Container 
identification 
Incorrect label (of the same patient) is 
assigned to a container 
1-Test performed with 
invalid sample 
2-Test not performed 
(sample rejected) 
1-Misleading 
result 
2-No result 
Extractor error 
RM staff 
inspection; Lab 
technician 
inspection 
5 2 1 10 Training and practicing 
Blood extraction 
Extractor forgets to use heparin for specific 
extraction 
1-Test performed with 
invalid sample 
2-Test not performed 
(sample rejected) 
1-Misleading 
result 
2-No result 
Extractor error 
RM staff 
inspection 
5 1 1 5 Training and practicing 
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Table 7. FMEA of CE (Continued) 
Extraction Center (CE)                     
Step of Process Failure Mode Immediate Effects End effects Causes 
Methods of 
Detection  
S P D RPN Action Recommended 
Blood extraction 
Extraction is performed without 
meeting the requirements of extraction 
(fasting, medication, diet, time of 
extraction, etc.) 
Test performed 
with inappropriate 
sample 
Misleading result 
Patient error (patient 
negligence; motivation); 
Extractor error (not confirm); 
Instruction not well 
communicated to patient 
Lab physician 
validation of 
extreme result; 
Doctor doubts 
of result 
5 3 4 60 
Better instruction to patient; 
extractor double confirms 
before extraction 
Blood extraction 
Contaminated materials (e.g. containers 
contaminated by  microorganisms, 
unexpected substances, etc.) are used 
in extraction 
Test performed 
with invalid sample 
Misleading result 
CDB auxiliary staff error 
(internal quality control of 
suppliers) 
Lab physician 
validation of 
result 
5 1 3 15 No 
Blood extraction 
Containers used are not in a good 
condition (broken, opened, not well 
protected from light, etc.) 
1-Test performed 
with invalid sample 
2-Test not 
performed (sample 
rejected) 
1-Misleading 
result 
2-No result 
CDB auxiliary staff error 
(internal inspection before 
use) 
Extractor 
inspection;  
RM staff 
inspection 
5 2 2 20 
Auxiliary staff checks when 
re-loading materials for each 
cubicle; Extractor checks 
before using 
Blood extraction 
Insufficient sample is obtained during 
extraction 
Test not 
performed (new 
request necessary) 
No result 
Extractor error;  
Patient physical condition 
Extractor 
inspection;  
Lab technician 
inspection 
4 2 1 8 
Skill and communicational 
training for extractor 
Blood extraction 
Patient has adverse event during or 
after extraction (e.g. allergy, faint, etc.) 
1-Patient 
jeopardized 
2-Incomplete 
extraction 
1-Patient 
adverse event 
2-Delayed result 
Accident;  
Patient physical condition; 
Instruction not well 
communicated to patient; 
Extractor error 
CDB staff 
observation 
5 1 1 5 
Skill and communicational 
training for extractor 
Sample storage 
Sample is stored in incorrect condition 
or container (e.g. frozen, 37ºC, 0ºC, 
light-protected, culture time, etc.) 
Test performed 
with invalid sample 
Misleading result 
Extractor error; CDB auxiliary 
staff error; 
Equipment malfunction 
RM auxiliary 
staff 
inspection; Lab 
technician 
inspection 
5 2 2 20 
Automatic alert for 
incubators malfunction; staff 
training (strictly follow the 
required condition); register 
start time-end time on tube 
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Table 8. FMEA of CE (Reception of Urine) 
Reception of Urine                     
Step of Process Failure Mode 
Immediate 
Effects 
End effects Causes Methods of Detection  S P D RPN Action Recommended 
Urine sample 
collection 
Urine sample collection time is 
incorrect (e.g. "24h" instead of 
"random") 
Test performed 
with 
inappropriate 
sample 
Inaccurate result 
Patient physical condition;  
Instruction not well 
communicated to patient 
Urine Reception staff 
question patient 
3 4 3 36 
Better instruction to 
patient; staff confirm 
before reception 
Urine sample 
collection 
Insufficient sample of urine is given 
by the patient 
Test not 
performed 
No result 
Patient physical condition;  
Instruction not well 
communicated to patient 
Urine Reception staff 
inspection; 
Lab technician 
inspection 
4 2 1 8 
Better instruction to 
patient; staff confirm 
before reception 
Urine sample 
collection 
No sample is received from patient 
(empty containers; patient does not 
bring 24h urine or leaves without 
giving sample) 
Test not 
performed 
No result 
Patient physical condition;  
Instruction not well 
communicated to patient 
Urine Reception staff 
inspection;  
Coordinator checks 
report of "Not 
Received" samples in 
SIL 
4 4 1 16 
Better instruction to 
patient 
Urine sample 
collection 
Container without additives is used 
to collect "24h urine with additives" 
Test performed 
with 
inappropriate 
sample 
Misleading result 
Patient error; 
Urine Reception staff error 
(forgets to add additives) 
Instruction not well 
communicated to patient 
Lab physician 
validation of result 
5 4 2 40 
Better instruction to 
patient; staff confirm 
before reception 
Urine 24h volume 
calculation 
The sum of Urine 24h volume is 
incorrectly calculated and registered 
(if >1 bottle) 
Incorrect data for 
calculation of 
final result 
Misleading result 
(extreme cases) 
Urine Reception staff error 
Doctor doubts of 
result 
5 1 4 20 
Staff register immediately 
after receiving the sample 
(avoid queuing the samples 
for later action. It is better 
to have the patient wait for 
a while holding their own 
samples) 
Urine 24h volume 
registration 
Urine 24h volume is not registered 
on diuresis sheets 
No data for 
calculation of 
final result 
Incomplete 
result 
Urine Reception staff error 
RM staff inspection; 
Lab physician 
validation of result 
3 2 1 6 
Staff register immediately 
after receiving the sample 
(without queuing the 
samples for later action. It 
is better to have the 
patient wait for a while 
holding their own samples) 
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Table 8. FMEA of CE (Reception of Urine) (Continued) 
Reception of Urine                     
Step of Process Failure Mode Immediate Effects End effects Causes 
Methods of 
Detection  
S P D RPN Action Recommended 
Urine 24h volume 
registration 
Urine 24h volume is assigned to another 
patient on diuresis sheets 
Incorrect data for 
calculation of final 
result 
Misleading result 
(extreme cases) 
Urine Reception staff 
error 
Doctor doubts 
of result 
5 1 4 20 
Staff register immediately after 
receiving the sample (without 
queuing the samples for later 
action. It is better to have the 
patient wait for a while holding 
their own samples) 
Sample 
identification 
Another patient's label is assigned to the urine 
sample container 
Sample incorrectly 
identified 
Misleading result 
Urine Reception staff 
error 
Undetectable 5 1 5 25 Training and practicing 
Sample aliquoting 
Auxiliary staff forgets to aliquot sample from 
24h urine 
Test not 
performed 
No result 
Urine Reception staff 
error 
Coordinator 
checks report 
of "Not 
Received" 
samples in SIL 
4 3 1 12 
Staff take aliquot immediately 
after receiving the sample 
(without queuing the samples 
for later action. It is better to 
have the patient wait for a 
while holding their own 
samples) 
Sample aliquoting 
24h urine (if >1 bottle) not mixed before 
aliquoting 
Inaccurate data for 
calculation of final 
result 
Inaccurate result 
Urine Reception staff 
error 
Undetectable 3 2 5 30 
Staff take aliquot immediately 
after receiving the sample 
(without queuing the samples 
for later action. It is better to 
have the patient wait for a 
while holding their own 
samples) 
Urine sample 
reception 
Samples of different patients are cross-
contaminated 
Test performed 
with inappropriate 
sample 
Misleading result 
Urine Reception staff 
error 
Undetectable 5 1 5 25 
Staff wear gloves all the time; 
manage only one sample at a 
time; keep the working area 
organized and clean 
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4.4.4 Pre-analytical Phase: Reception of Samples 
Table 9. FMEA of RM 
Reception of Samples                     
Step of Process Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RPN Action Recommended 
Sample inspection 
Samples for other departments 
(e.g. AP, MIC Urgent) are accepted 
by error 
1-Request for other 
departments activated by 
error 
2-Short delayed reception of 
corresponding departments 
No effect RM reception staff error 
RM staff inspection in 
following processes 
1 4 1 4 
Clear instruction for 
clients of the exact 
reception location 
Sample inspection 
Samples without payment 
agreement are accepted and sent 
for test (e.g. samples from 
unauthorized lab of a client) 
Test performed without 
payment 
No result RM reception staff error 
Secretary staff 
inspection; 
Finance inspection 
4 3 1 12 
SIL pre-sets accepted 
clients list 
Sample inspection 
Insufficient sample is received 
(container is in good condition) 
Test not performed No result 
Human error (extractor 
error, patient physical 
condition); Bad 
communication with 
patient 
Lab technician 
inspection 
4 2 1 8 
Training for extractor 
and external clients; 
Better communication 
with external clients 
Sample inspection 
Containers used are not in good 
condition (broken, opened, not 
well protected from light, etc.) 
Test not performed (sample 
rejected) 
No result 
Transportation accident; 
Container defects 
RM staff inspection;  
Lab technician 
inspection 
4 3 1 12 
Improve tube 
protection measures 
for the frequently 
broken origins/ clients 
Sample inspection Coagulated sample is received Test not performed No result 
Extractor error (forgets to 
add anticoagulants, uses 
the wrong container, etc.) 
RM staff  inspection;  
Lab technician 
inspection 
4 4 2 32 
Extractor/ clients 
training (correct tube/ 
additives) 
Sample inspection Hemolysis sample is received Test not performed No result 
Storage and transportation 
condition; Accident; 
Extractor error 
(inappropriate extraction) 
RM staff inspection;  
Lab technician 
inspection 
4 4 1 16 
Extractor/ clients 
training (correct tube/ 
additives); strictly 
follow the storage 
requirements in all the 
processing steps 
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Table 9. FMEA of RM (Continued) 
Reception of Samples                     
Step of Process Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RPN Action Recommended 
Sample inspection 
Contaminated sample is received 
(e.g. contaminated by 
microorganisms, other samples, 
unexpected substances, etc.) 
Test performed with 
invalid sample 
1-Misleading 
result 
2-No result 
Storage and 
transportation condition; 
Accident; Extractor error 
(inappropriate 
extraction) 
Lab technician or lab 
physician validation of 
result 
5 2 3 30 
Strictly follow the storage 
requirements in all the 
processing steps 
Sample inspection 
Patient name on original sample 
containers (with original label) 
does not match the name on the 
request 
1-Test performed with 
another patient's sample 
2-Sample rejected (test 
not performed) 
1-Misleading 
result 
2-No result 
Ward nurse or external 
clients error (mis-place 
the samples and 
requests) 
RM staff inspection 5 2 2 20 
Good organization of samples 
in origins; Clients check before 
sending; RM staff paste new 
label without covering the 
original label so in the 
following processes staff can 
double check 
Sample inspection 
Sample not identified or not 
identifiable is received 
Test not performed 
(sample rejected) 
No result 
Ward nurse or external 
clients error 
RM staff inspection; 
Lab technician double 
checks in following 
processes 
4 1 1 4 
Clear instruction for 
extractors/ clients: how to 
appropriately label and 
identify samples, rejecting 
rule should be respected 
Sample inspection 
Sample with incomplete 
information on the label is 
received (e.g. one patient has 
multiple samples but without 
distinguishing the extraction time 
or order of different sampling) 
Test not performed 
(sample rejected) 
No result External clients error RM staff inspection 4 2 1 8 
Clear instruction for clients: 
how to appropriately label 
and identify samples, rejecting 
rule should be respected 
Sample inspection 
Number of samples received does 
not match the necessary number 
on the request 
1-Test not performed 
2-Delayed sample 
reception 
1-No result 
2-No effect 
Extractor error; 
Transportation loss; 
Label printing error 
RM staff inspection 4 2 1 8 
Reception CE checks label 
number with request; Design 
clearer info on request (e.g. 
total number of tests or 
tubes); Clients check before 
sending 
Sample inspection 
Sample is in incorrect container 
(i.e. with incorrect additives) 
1-Test performed with 
invalid sample 
2-Test not performed 
(sample rejected) 
1-Misleading 
result 
2-No result 
Extractor (or other 
sample collector) error 
RM staff inspection 5 4 1 20 
Training for extractor/ 
external clients 
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Table 9. FMEA of RM (Continued) 
Reception of Samples                     
Step of Process Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RPN Action Recommended 
Request activation 
Request is closed or already 
activated (from ward or 
external clients) 
Test not performed (sample 
rejected) 
No result 
Doctor error; Nurses 
error 
RM staff inspection 4 4 1 16 
Nurses confirm request is new 
before taking samples from 
patient; Pre-set in SIL that 
closed or activated requests 
can only be printed with 
special authorization 
Sample identification 
Incorrect label (of the same 
patient) is assigned to a 
container 
1-Test performed with 
invalid sample 
2-Test not performed 
1-Misleading 
result 
2-No result 
RM reception staff 
error 
RM staff inspection in 
following processes; Lab 
technician inspection 
5 2 1 10 Training 
Sample identification 
Another patient's label is 
assigned to the sample 
Sample incorrectly 
identified 
Misleading result 
RM reception staff 
error 
Lab physician validation 
of result 
5 1 4 20 Training 
Sample registration in 
SIL 
Sample is not registered in 
SIL for "Entrada" or "Salida" 
or  is scanned multiple times 
Lack of or incorrect 
traceability in SIL 
No effect 
RM auxiliary staff 
error 
Undetectable 1 3 5 15 No 
Sample registration in 
SIL 
Sample label is damaged 
and/ or unreadable by 
machine 
Sample not automatically 
registered (manual entry) 
No effect 
Storage or 
transportation 
accident (label is 
eroded or broken) 
RM staff inspection 1 2 1 2 
Protect the labels with tape 
when storing in ice water 
Request introduction 
Incomplete request is 
received (e.g. patient data 
incomplete for gene tests; 
test name not specified; 
external clients address 
unclear) 
1-Test performed with 
insufficient information 
2-Delayed test 
3-No result received 
1-Incomplete 
result 
2-Delayed result 
3-No result 
External clients or 
HCB doctor error 
RM staff inspection; 
Secretary staff inspection 
(review process); Lab 
physician validation of 
result 
4 4 1 16 
Training for doctor and 
external clients about 
completion of request 
Request introduction 
Requested test does not 
exist in SIL / catalog 
Test not performed (sample 
rejected) 
No result 
External clients 
error;  
Bad communication 
with external clients 
RM staff inspection 4 3 1 12 
Unify the catalog for test 
selectors (in SAP-SIL-Excel 
library-Clients System) and 
update regularly; Avoid 
private communication with 
external clients 
Request introduction 
Requested test name does 
not correspond exactly with 
that in excel library or HCB 
catalog webpage 
1-Inappropriate test 
performed 
2-Delayed test 
1-No result (for 
expected test) 
2-Delayed result 
Design of 
terminology not 
standardized or 
consistent 
RM staff inspection; Lab 
physician validation of 
result 
4 3 1 12 
Unify the catalog for test 
selectors (in SAP-SIL-Excel 
library-Clients System) and 
update regularly; Avoid 
private communication with 
external clients 
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Table 9. FMEA of RM (Continued) 
Reception of Samples                     
Step of Process Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RPN Action Recommended 
Request introduction 
Request is introduced with 
some error (patient data, 
test name, external client 
data, etc.) 
1-Incorrect interpretation 
2-Inappropriate test 
performed 
3-No result received 
1-Misleading 
result 
2-No result (for 
expected test) 
3-No result report 
received 
RM reception staff error; 
External client bad hand-
writing; Multiple 
requests on 1 paper 
Secretary staff 
inspection (review 
process); Lab physician 
validation of result 
5 3 2 30 
Clients all use SIL interfaces; 
external request forms are 
standardized; clear 
instruction of compulsory 
information and clear hand-
writing; avoid multiple 
requests on one page 
Request introduction 
Request is not introduced in 
SIL 
Test not performed No result RM reception staff error 
RM staff inspection of 
pending samples;  
Secretary staff 
inspection (review 
process) 
4 1 2 8 
Use one particular desk for 
big clients with daily 
multiple requests 
Request introduction 
Pending samples (including 
requests) are not managed 
(e.g. incomplete request 
pending for secretary 
communication with client; 
or multiple >3 request 
pending for secretary 
manual introduction) 
1-Test not performed 
2-Delayed test 
1-No result 
2-Delayed result 
RM reception staff error 
RM staff inspection;  
Secretary staff 
inspection 
4 2 2 16 
RM first checks the number 
of samples vs. requests; 
Specific area identified for 
pending samples (one 
request corresponds one 
bag of samples identified 
with header label with 
request number); check and 
empty the area daily by a 
responsible person 
Sample storage 
Sample is stored in incorrect 
condition (frozen, 37º, 0º, 
light-protected, culture time, 
etc.) 
1-Test performed with 
invalid sample 
2-Test not performed 
(sample rejected) 
1-Misleading 
result 
2-No result 
RM staff error; Storage 
equipments malfunction 
RM staff inspection; 
Lab technician 
inspection; Lab 
physician validation of 
result 
5 2 2 20 
Automatic alert for 
incubators malfunction; 
staff training (strictly follow 
the required condition); 
register start time-end time 
on tube 
Processing: Centrifuge 
Sample is centrifuged in 
incorrect condition (e.g. 
incorrect temperature, 
duration) 
1-Test performed with 
invalid sample 
2-Lab technician centrifuge 
again 
1-Misleading 
result 
2-No effect 
RM staff error 
Lab technician 
inspection 
5 2 4 40 
Group the samples in 
advance according to the 
centrifuge condition; set a 
fixed the duration and no 
need to adjust every time 
Processing: Centrifuge Centrifuge does not work Short delayed processing No effect Hardware malfunction 
Lab technician 
inspection 
1 1 1 1 Backup plan (centrifuge) 
 66 
 
Table 9. FMEA of RM (Continued) 
Reception of Samples                     
Step of Process Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RPN Action Recommended 
Processing: Aliquot 
process 
Aliquoting machine does not work 
(e.g. incorrect setting of the robot 
"No cap", other incidences e.g. 
tubes stuck) 
1-Short delayed 
processing 
2-Manual aliquot process 
performed 
No effect 
Hardware or software 
malfunction; Aliquoting 
technician error 
Aliquoting technician 
inspection 
1 3 1 3 
Training for technicians 
focusing on incidences 
treatment (to avoid 
occurrence and shorten 
resolution time) 
Processing: Aliquot 
process 
Aliquoting pipette goes too deep 
into the primary tube 
1-Manual aliquot process 
performed 
2-Inappropriate sample 
sent to services and lab 
technician performs 
aliquoting 
No effect 
Software design; 
Aliquoting technician 
error (not check sample 
volume before loading 
samples) 
Aliquoting technician 
inspection; Lab 
technician inspection 
1 3 1 3 
Set a criteria for 
samples that can be 
automatically aliquoted 
and technician always 
checks the criteria 
Processing: Aliquot 
process 
Sample is cross-contaminated (E.g. 
a drop of sample falls into another 
aliquot; not change pipette, etc.) 
Test performed with 
invalid sample 
Misleading result Hardware malfunction Undetectable 5 1 5 25 
Aliquoting technician 
weekly checks the 
machine working status 
by close observation 
Processing: Manual/ 
Auto aliquot process 
Sample volume is insufficient for 
aliquoting 
Test not performed No result 
Extractor error;  
Patient physical 
condition 
Aliquoting technician 
inspection; Lab 
technician inspection 
4 4 1 16 
A smart system should 
be developed in SIL to 
tell: for all the tests of 
one patient, the 
minimum volume and 
number of containers 
necessary 
Processing: Manual 
aliquot process 
Samples of different sampling 
time points (for the same patient) 
are mixed by error (for curve test) 
Sample inaccurate or 
cross-mixed 
Misleading result 
RM aliquoting technician 
error 
Undetectable 5 1 5 25 
Print on labels a special 
sign for curve test 
samples 
Processing: Manual 
aliquot process 
Some primary labels cannot 
generate secondary labels (e.g. 
prefix 057) 
Use primary label instead No effect SIL bad mapping 
Lab technician 
inspection 
1 3 3 9 Fix the programming 
Processing: Manual 
aliquot process 
Secondary label of another patient 
is assigned to an aliquot sample 
1-Sample incorrectly 
identified (same test as 
expected) 
2-Inappropriate test 
performed (different test 
from expected) 
1-Misleading 
result 
2-No result (for 
expected patient) 
RM aliquoting technician 
error (during blood or 
urine aliquoting process) 
Undetectable 5 1 5 25 
Better design in SIL 
label-printing page (e.g. 
categorize by sample 
type: urine or blood, 
etc.); technician 
manages one patient 
sample at a time in a 
separated rack 
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Table 9. FMEA of RM (Continued) 
Reception of Samples                     
Step of Process Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RPN Action Recommended 
Processing: Manual 
aliquot process 
Secondary label (same patient) of 
another test/ destination is 
incorrectly assigned to an aliquot 
sample 
Inappropriate test 
performed 
No result (for 
expected test) 
RM aliquoting technician 
error (during blood or 
urine aliquoting process) 
Undetectable 4 1 5 20 
Better design in SIL label-
printing page (e.g. 
categorize by sample 
type: urine or blood, etc.); 
technician manages one 
patient sample at a time 
in a separated rack 
Processing: Manual 
aliquot process 
Sample is cross-contaminated 
(E.g. Use other patient's sample 
to make the aliquot sufficient; 
not change pipette, etc.) 
Test performed with 
invalid sample 
Misleading result 
RM aliquoting technician 
error (during blood or 
urine aliquoting process) 
Undetectable 5 1 5 25 
Double check before 
using the substitute; 
Training 
Processing: Manual 
aliquot process 
Sample transfer is not performed 
during manual aliquot process 
No aliquot sample No result 
RM aliquoting technician 
error (during blood or 
urine aliquoting process) 
Coordinator checks 
report of "Not 
Received" samples in 
SIL; Lab technician 
inspection of worklist 
4 2 1 8 
Clearly label the tube 
racks during manual 
aliquoting 
Urine 24h volume 
registration 
Incorrect urine 24h volume is 
registered 
Incorrect data for 
calculation of final result 
Misleading result 
(extreme cases) 
RM staff error Doctor doubts of result 5 2 3 30 Double check 
Urine 24h volume 
registration 
Urine 24h volume is not register 
for one patient or urine 24h 
sheet is lost before registration 
No data for calculation 
of final result 
Incomplete result 
RM staff error; 
Transportation loss 
Lab physician 
validation of result 
3 2 1 6 Double check 
Urine 24h volume 
registration 
Registration of urine 24h volume 
is delayed 
Short delayed process No effect RM staff error RM staff inspection 1 3 1 3 No 
Sample transportation 
Pneumatic pipe does not work or 
work with error 
Manual transportation No effect 
Hardware or 
Software malfunction 
CDB staff observation 1 2 1 2 
Setup pneumatic pipe 
alert system; Backup plan 
for human transportation 
Sample transportation 
Sample is transported under 
inappropriate condition (internal 
and external) 
1-Test performed with 
invalid sample 
2-Test not performed 
(sample rejected) 
1-Misleading 
result 
2-No result 
RM staff error (e.g. some 
samples cannot be sent 
by pneumatic pipe; 
forget to add ice, etc.); 
Lack of training 
RM staff inspection; 
Lab technician 
inspection 
5 2 2 20 
Training focusing on 
frequent occurrence 
clients 
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Table 9. FMEA of RM (Continued) 
Reception of Samples                     
Step of Process Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RPN Action Recommended 
Sample transportation 
Sample is lost (during 
internal processing or 
transportation from/to other 
external labs) 
No result No result 
RM staff error; 
Transportation loss 
Coordinator checks 
report of "Not 
Received" samples in 
SIL 
4 2 1 8 
Training focusing on frequent 
occurrence clients 
Sample transportation 
Sample is distributed to 
incorrect destination 
Short delayed process No effect 
RM staff error (pneumatic 
pipe code incorrect entry; 
mis-identify the code, place 
tubes in incorrect racks, 
manual transportation by 
error, etc.) 
Lab technician 
inspection 
1 3 1 3 No 
Sample transportation 
Sample is left in incorrect 
storage equipment in labs 
(when there is no technician 
to receive samples) 
1-Test performed with 
invalid sample 
2-Test not performed 
(sample rejected) 
1-Misleading 
result 
2-No result 
RM staff error 
Lab technician 
inspection 
5 2 1 10 
Better training (which sample 
requires which condition) 
Sample transportation 
Sample transportation is 
delayed 
Short delayed process No effect RM staff error RM staff inspection 1 3 1 3 
Review of collection interval 
and see if necessary to change; 
backup staff transports if 
previous staff not returns on 
time 
Re-extraction request 
Email notifying re-extraction 
is not sent to reception CE 
(in case of sample invalid or 
lost) 
Test not performed No result RM coordinator error 
RM coordinator 
inspection 
4 2 4 32 
Fixed schedule for coordinator 
(email sender)  and reception 
staff (counter 4) to manage re-
extraction request and other 
special cases; Create an alert 
function in SIL to remind of 
pending re-extraction request 
Request archiving 
Daily requests are archived 
in incorrect category (e.g. 
"Derivation"-requests to be 
sent to external analysis labs; 
"Incidence"-requests with 
additional information to be 
archived for longer time) 
Lack of paper traceability 
(all necessary information 
is registered electronically 
in SAP or SIL as backup) 
No effect RM reception staff error Undetectable 1 2 5 10 No 
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4.4.5 Pre-analytical and Post-analytical Phase: Secretary UGC 
Table 10. FMEA of Secretary UGC for Pre-analytical and Post-analytical 
Secretary UGC                     
Step of 
Process 
Failure Mode Immediate Effects End effects Causes 
Methods of 
Detection 
S P D RPN Action Recommended 
Request 
introduction 
Request is introduced 
with some error (patient 
data, test name, external 
client data, etc.) 
1-Incorrect 
interpretation 
2-Inappropriate test 
performed 
3-No result received 
1-Misleading result 
2-No result (for 
expected test) 
3-No result report 
received 
Secretary staff error; 
External clients bad 
hand-writing;  
Multiple requests on 1 
paper 
Secretary staff 
inspection (review 
process) 
5 3 2 30 
External clients all use SIL interfaces; 
External request forms are standardized; 
Clear instruction of compulsory 
information and clear hand-writing; 
Avoid multiple requests on one page 
Request 
introduction 
Request is not introduced 
in SIL 
1-No request in SIL 
2-Sample without label 
3-Test not performed 
No result Secretary staff error 
Secretary staff 
inspection (review 
process) 
4 1 2 8 
RM first checks the number of samples 
vs. Requests; Specific area identified for 
pending samples (one request 
corresponds one bag of samples 
identified with header label with request 
number); Check and empty the area 
daily by a responsible person 
Request scan Request is not scanned Lack of traceability in SIL No effect 
Secretary staff error; 
Hardware malfunction 
Secretary staff 
inspection (review 
process) 
1 1 2 2 No 
Request scan Scanner does not work 
Delayed archiving and 
uploading requests in SIL 
No effect Hardware malfunction 
Secretary staff 
observation 
1 1 1 1 No 
Request 
inspection 
Errors of the manually 
introduced requests are 
not identified (patient 
data, test name, external 
client data, etc.) 
1-Incorrect 
interpretation 
2-Inappropriate test 
performed 
3-No result received 
1-Misleading result 
2-No result (for 
expected test) 
3-No result report 
received 
Secretary staff error; 
External clients bad 
hand-writing 
Lab physician 
validation of result (in 
case of confusing or 
incomplete 
information); 
Undetectable for 
other cases 
5 2 4 40 
External clients all use SIL interfaces; 
External request forms are standardized; 
Clear instruction of compulsory 
information and clear hand-writing; 
Avoid multiple requests on one page 
Request 
inspection 
Erroneous modification 
of request is introduced 
(patient data, test name, 
external client data, etc.) 
1-Incorrect 
interpretation 
2-Inappropriate test 
performed 
3-No result received 
1-Misleading result 
2-No result (for 
expected test) 
3-No result report 
received 
Secretary staff error 
Lab physician 
validation of result (in 
case of confusing or 
incomplete 
information); 
Undetectable (for 
other cases) 
5 1 4 20 
External clients all use SIL interfaces; 
External request forms are standardized; 
Clear instruction of compulsory 
information and clear hand-writing; 
Avoid multiple requests on one page 
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Table 10. FMEA of Secretary UGC for Pre-analytical and Post-analytical (Continued) 
Secretary UGC                     
Step of 
Process 
Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RPN Action Recommended 
Request 
modification 
Incorrect test is added to an activated 
request (e.g. unexpected test, impossible 
test, etc.) 
Inappropriate test 
performed 
No result (for 
expected test) 
Secretary staff error; 
Lack of training 
Undetectable 4 2 5 40 
Standardized category or 
test code to ease 
communication; Better 
design of test selection 
page in SIL; Training 
Request 
modification 
A new test which is reasonably added by 
a doctor is not accepted (when in the lab 
there is additional sample available for 
adding such test) 
New request needs to 
be ordered 
Delayed result 
Secretary staff error; 
Lack of training 
Undetectable 4 1 5 20 
Program SAP-SIL to 
automatically search for 
available samples for the 
newly requested test 
Request 
modification 
Added test is not registered in IMP-815 
"Register Modification of Request" 
Lack of traceability No effect Secretary staff error Undetectable 1 1 5 5 
Program SAP-SIL to 
automatically search for 
available samples for the 
newly requested test; 
doctor can add it directly in 
SAP 
Incidence 
management 
Incidence (internal and external) is 
neglected (e.g. not managed, not 
followed-up or not registered or updated 
in the system) 
1-Incidence not treated 
2-Incidence pending 
resolution 
1-No result 
2-Delayed 
result 
Secretary staff error 
External/ internal clients 
ask for information 
4 1 3 12 No 
Incidence 
reporting 
External/ internal clients are not 
informed of CDB process changes timely 
(e.g. certain test cannot be performed 
for a while) 
1-No test performed 
2-Delayed test 
1-No result 
2-Delayed 
result 
Secretary staff error 
External/ internal clients 
ask for result 
4 2 2 16 
Create a client distribution 
list within each change 
announcement, instead of 
separately 
Information 
reporting 
Incorrect information is given to the 
external/ internal clients (e.g. how 
many/ what type of containers are 
needed for a test; TAT, etc.) 
Incorrect sample 
management (e.g. 
invalid sample, 
insufficient sample, etc.) 
1-No result 
2-Delayed 
result 
Internal source 
information error; 
Communication error; 
Lack of training 
RM staff inspection when 
receiving samples; 
External/ internal clients 
ask for result; 
Undetectable (for other 
cases) 
4 1 4 16 
Standardized category or 
test code; Training to staff 
and clients about 
information searching 
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Table 10. FMEA of Secretary UGC for Pre-analytical and Post-analytical (Continued) 
Post-analytical phase: Secretary UGC                   
Step of 
Process 
Failure Mode Immediate Effects End effects Causes 
Methods of 
Detection 
S P D RPN Action Recommended 
Result 
management 
Result follow-up for 
external big clients in SIL 
is not done every day 
Delayed tracking No effect Secretary staff error 
Secretary staff 
inspection in 
successive follow-up 
1 2 1 2 
SIL auto report for detecting ALL 
delayed results 
Result 
management 
Alert for the result which 
is beyond TAT is not sent 
to services 
Not detect incidence 
timely 
Delayed result Secretary staff error 
Secretary staff 
inspection in 
successive follow-up 
4 2 1 8 
SIL auto report for detecting ALL 
delayed results 
Result 
management 
Patient private 
information is not 
deleted from electronical 
document 
Patient private 
information received 
by external 
organization 
Non-compliance of 
Personal Data Protection 
Law (LOPD: Ley Orgánica 
de Protección de Datos 
de Carácter Personal) 
Secretary staff error Undetectable 5 1 5 25 
Encrypt all documents to be sent 
(better automatically) 
Result 
management 
Not all results are sent 
out to external client (by 
post or email) 
No result delivered 
1-No result 
2-Delayed result 
Secretary staff error; 
Hardware or software 
malfunction; 
Transportation lost 
Secretary staff 
inspection (result 
checklist); External 
clients ask for result 
4 2 1 8 
Better design of the printing order 
in SIL (for easy detection and 
continuation after PC is dead) 
Result 
management 
Result is sent to incorrect 
external client (by post or 
email) 
No result received 
1-No result 
2-Delayed result 
Secretary error; External 
clients error (incomplete 
or incorrect information) 
External clients ask 
for result 
4 1 3 12 
Confirm external clients 
information annually; Compulsory 
address information on external 
request form (where to return 
result/sample) 
Request 
archiving 
Request is not archived Lack of traceability No effect 
Secretary staff error; 
Hardware malfunction 
Secretary staff 
inspection; External 
clients ask for result 
1 2 3 6 No 
Sample 
transportation 
Sample is not sent back 
to external client as 
required 
No sample received by 
external client to 
perform test 
1-No result 
2-Delayed result 
Secretary staff error 
Secretary staff 
inspection; External 
clients ask for 
samples 
4 1 1 4 
List the external clients that needs 
sample return; Store the samples in 
a special place; Check and empty 
the sample storage place daily by a 
responsible person 
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4.4.6 Analytical Phase: Core BM General 
Table 11. FMEA of Core BM General 
Core BM: General                     
Step of Process Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RPN Action Recommended 
General No electricity 
1-All electronic devices 
stop working 
2-Delayed all processes 
Delayed result 
Accident with electricity 
supply; Hardware error 
CDB staff observation 4 1 1 4 
Immediate recovery plan 
and back-up electricity 
system 
General 
Lack of kits, reagents or 
materials supply 
Delayed processes Delayed result 
Technician error 
(inadequate internal 
order); Supplier error 
(incorrect or delayed 
delivery) 
Technician inspection 4 3 1 12 
Automatic alert in supply 
registration system, and 
technician checks regularly 
General 
Reagents (primers, Amplitaq, 
Exostar, Bigdye, EdgeBio, 
formamide, etc.) contaminated 
by  microorganisms, samples, 
unexpected substances, etc. 
are used  
1-Test performed with 
invalid sample 
2-Reactions failure and 
immediate repetition 
Misleading result 
Supplier error (lack of 
quality control); 
Technician error 
(reagents are 
contaminated during 
operation) 
Technician QC validation 5 1 2 10 No 
General 
Expired reagents are used 
(primers, Amplitaq, Exostar, 
Bigdye, EdgeBio, formamide, 
etc.) 
Reactions failure 
and immediate repetition 
No effect 
Technician error (lack of 
inspection) 
Technician QC 
validation; Technician 
inspection 
1 1 2 2 
Register expiration date 
directly on reagents on 
arrival and on aliquots after 
preparation 
General 
Auxiliary equipments 
(centrifuge, incubator, etc.) do 
not work 
Short delayed process and 
back-up equipments used 
No effect 
Equipments 
malfunction;  
Technician error (lack of 
maintenance) 
Technician observation 1 2 1 2 
Technician training of 
immediate recovery; always 
have back-up equipments 
General 
QIAxcel, spectrophotometer, 
electrophoresis equipments do 
not work 
Short delayed process and 
manual operation 
No effect 
Equipments 
malfunction;  
Technician error (lack of 
maintenance) 
Technician observation 1 2 1 2 
Technician training of 
immediate recovery; always 
have back-up equipments 
Network 
Connection 
The connection between SIL 
and Robot Sample Tracking 
database is lost 
Process interrupted and 
short delayed process 
No effect Network error Technician observation 1 2 1 2 No 
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Table 11. FMEA of Core BM General (Continued) 
Core BM: General                     
Step of Process Failure Mode Immediate Effects End effects Causes 
Methods of 
Detection 
S P D RPN Action Recommended 
Sample storage 
Sample (blood sample, 
tissue/biopsy, neonatal blood 
paper, amniotic fluid, DNA, etc.) 
storage condition is incorrect 
1-Test performed with 
invalid sample 
2-Sample rejected and 
test not performed 
1-Misleading result 
2-No result 
Storage equipments 
malfunction; Technician 
error (storage location; 
lack of maintenance) 
Technician 
inspection; 
Technician QC 
validation 
5 2 1 10 
Clear position identification 
(labels, fixed position) for 
each category of sample 
Sample storage 
Sample (primary, intermediate or 
final DNA sample) is lost 
Test not performed No result 
Technician error (bad 
labelling); 
Transportation accident 
Technician or lab 
physician 
inspection of 
worklist 
4 1 1 4 
Clear position identification 
(labels, fixed position) for 
each category of sample 
Sample 
transportation 
Extracted DNA or aliquot primary 
samples are distributed to 
incorrect destinations 
1-Delayed test 
2-Short delayed process 
and re-distribute 
Delayed result 
Technician error; Design 
of secondary label (it 
needs experience to 
judge the destination) 
Core BM clients 
inspection 
4 2 1 8 
Design more reader-friendly 
secondary label (e.g. use 
"MIC" instead of "017")  
Sample 
transportation 
DNA quantification report is not 
sent back to client as requested 
(together with the amniotic fluid 
DNA sample) 
Short delayed process 
and report re-sent 
No effect Technician error 
Core BM clients 
ask for report 
1 1 1 1 
Upload report to shared 
drive and for client checking 
Test repetition 
Another patient's sample is 
selected for repetition 
Test performed with 
other patient's sample 
Misleading result Technician error 
Lab physician 
validation of 
sequencing result 
5 1 4 20 
For Robot searching: look up 
in the database manually 
(which position in which 
plate is the selected 
sample), then check if the 
Robot picks the correct 2D 
tube 
Test repetition 
Manual repetition (extraction, 
PCR, etc.) is not registered in SIL 
Lack of traceability in 
SIL 
No effect Technician error Undetectable 1 1 5 5 No 
Archiving 
Worklists, quantification results, 
electrophoresis photos, sex PCR 
QC results (all intermediate 
results) are not archived in shared 
drive or notebooks 
Lack of information and 
traceability 
No effect Technician error Undetectable 1 1 5 5 No 
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4.4.7 Analytical Phase: Extraction Platform 
Table 12. FMEA of Extraction Platform 
Extraction Platform: Sample Reception                   
Step of Process Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RPN Action Recommended 
Sample 
inspection 
Sample (sample ID, number of 
samples) and worklist do not 
match (e.g. IBC neonatal blood 
sample is not programmed in 
worklist) 
1-Test not performed 
2-Delayed test 
3-Short delayed process 
1-No result 
2-Delayed result 
SIL worklist bad 
mapping (incorrect or 
incomplete);  
Transportation error or  
delay; Core BM clients 
error 
Technician inspection 4 3 1 12 
List clear information in 
worklist for 
comparison; check non-
receiving samples in 
worklist and follow-up 
Sample 
inspection 
Coagulated blood sample is 
received 
Manual extraction 
performed 
No effect Extractor error Technician inspection 1 2 1 2 No 
Sample 
inspection 
Hemolysis blood sample is 
received 
No effect No effect 
Extractor error; 
Transportation accident 
Technician inspection 1 2 1 2 No 
Sample 
inspection 
Contaminated sample is received 
(e.g. contaminated by 
microorganisms, samples, 
unexpected substances, etc.) 
1-Test performed with 
invalid sample 
2-Reactions failure and 
immediate repetition 
Misleading result 
Extractor error; RM staff 
or client processing 
error 
Lab physician validation 
of sequencing result 
5 1 4 20 
Remind to the clients 
about the pre-analytical 
requirements 
Sample 
inspection 
Insufficient primary sample is 
received 
1-Test not performed 
2-Manual extraction 
No result 
Sample obtaining 
difficulty (patient 
physical condition; 
extractor error, etc.) 
Technician inspection 4 2 1 8 No 
Sample 
inspection 
Insufficient DNA sample is 
received 
1-Test not performed 
2-Short delayed process 
No result 
Core BM clients 
extraction error 
Technician 
quantification check 
4 1 1 4 
Training to the clients; 
Ask for quantity and 
concentration 
information on the 
request 
Label 
management 
Secondary label for DNA 
(including extra aliquot DNA) is 
lost 
1-Test not performed (no 
aliquot sent to clients) 
2-Short delayed process 
1-No result 
2-Delayed result 
Technician error 
Technician inspection; 
Core BM clients ask for 
sample 
4 2 1 8 
Always put labels-
primary tubes-2ml DNA 
empty tubes together in 
1 bag, if not 
immediately treated 
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Table 12. FMEA of Extraction Platform (Continued) 
Extraction Platform: Pre-treatment/ Extraction (Automatic and manual) 
Step of Process Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RPN Action Recommended 
General 
extraction 
DNA extracted manually is 
insufficient (e.g. amniotic fluid 
sample) 
No more sample available 
for re-extraction 
1-No result 
2-Inaccurate 
result 
Primary sample 
quantity; Extraction 
accident; Technician 
error 
Technician 
quantification check 
4 3 1 12 
Training to the clients; Ask 
for quantity and 
concentration information 
on the request 
General 
extraction 
DNA extracted automatically is 
insufficient 
1-Extraction repetition 
2-Manual extraction 
No effect 
Sample quantity; 
Extraction accident 
Technician 
quantification check 
1 3 1 3 No 
General 
extraction 
Requested extraction or re-
extraction is not done 
Test not performed No result Technician error 
Technician inspection;  
Core BM clients ask for 
result 
4 1 2 8 
Fixed schedule to manage 
re-extraction request; 
Create an alert function in 
SIL to remind of pending 
request 
Manual 
Extraction/ Pre-
treatment 
Incorrect kit or reagent is used 
1-No more sample 
available for re-extraction 
2-Process failure 
(immediate repetition) 
No result Technician error 
Technician 
quantification check 
4 1 1 4 
Fixed area and grouped 
reagents for each 
operation; Clearly 
labelling of position of 
reagents 
Manual 
Extraction/ Pre-
treatment 
Incorrect volume of reagent is 
used; incorrect operation of 
auxiliary equipments (time, rpm, 
temperature, etc.) 
1-No more sample 
available for re-extraction 
2-Process failure 
(immediate repetition) 
3-No effect 
No result Technician error 
Technician 
quantification check 
4 1 1 4 No 
Manual 
Extraction/ Pre-
treatment 
Sample and intermediate labels 
(last 5 numbers hand-written) do 
not correspond to the same 
patient 
Sample incorrectly 
identified 
Misleading result 
Technician error 
(transfer error; bad 
labelling) 
Technician inspection by 
chance; Lab physician 
validation of sequencing 
result 
5 3 4 60 
Organize samples in short 
groups during operation; 
Avoid as much as possible 
the manual extraction 
Manual 
Extraction/ Pre-
treatment 
Primary sample (insufficient blood 
sample, tissue/biopsy, amniotic 
fluid, etc.) that must be extracted 
manually is treated automatically 
1-No DNA extracted (no 
more primary sample 
available for re-extraction) 
2-Process failure and 
immediate repetition 
No result Technician error Technician observation 4 1 1 4 
Clear position and 
organization of samples 
Automatic 
Extraction 
Extractors do not work Delayed test Delayed result Hardware malfunction Technician observation 4 2 1 8 No 
Sample transfer 
(Robot 0) 
Robot 0 does not work 
Manual sample transfer 
performed 
No effect Hardware malfunction Technician observation 1 3 1 3 No 
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Table 12. FMEA of Extraction Platform (Continued) 
Extraction Platform: Pre-treatment/ Extraction (Automatic and manual) 
Step of Process Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RPN Action Recommended 
Sample transfer 
(Robot 0) 
Necessary secondary tubes are 
not loaded to receive aliquot of 
blood samples or DNA samples 
No aliquots obtained and 
test not performed 
No result Technician error 
Technician inspection of 
additional labels; Core 
BM clients ask for 
sample 
4 3 1 12 
Always put labels-primary 
tubes-2ml DNA empty tubes 
together in 1 bag, if not 
immediately treated 
Automatic 
Extraction 
Accidents occur during automatic 
extraction (e.g. arm crashing, 
pipetting problems, etc.) 
1-Sample invalid 
2-Process failure and 
immediate repetition 
1-No result 
2-Delayed result 
Hardware malfunction Technician observation 4 2 1 8 
Aliquoting technician weekly 
checks the machine working 
status by close observation 
 
Extraction Platform: Quantification & Electrophoresis 
Step of Process Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RPN Action Recommended 
Quantification 
Quantification 
spectrophotometer does not 
work 
Short delayed QC process No effect Hardware malfunction Technician inspection 1 1 1 1 No 
Quantification 
Deviation operation of 
spectrophotometer, e.g. not 
cleaning, no or incorrect blank 
measurement, sample with 
bubble, etc. 
1-Test performed with 
poor quality DNA  
2-Incorrect quantification 
and immediate repetition 
No result Technician error 
Technician validation of 
quantification result; 
PCR QC; Core BM clients 
complaint 
4 1 1 4 Training 
Quantification 
Another patient's sample is taken 
to be quantified for QC 
Good quantification result 
assigned to poor quality 
DNA 
No result Technician error 
Core BM clients 
complaint before TAT; 
PCR QC 
4 1 1 4 No 
Quantification 
Poor quantification result is 
accepted during technician 
validation 
Test performed with poor 
quality DNA sample 
No result Technician error 
Core BM clients 
complaint before TAT; 
PCR QC 
4 1 1 4 Training 
Electrophoresis Electrophoresis does not work 
Short delayed process and 
back-up equipments used 
No effect Hardware malfunction Technician observation 1 1 1 1 No 
Electrophoresis 
Deviation operation, e.g. sample 
not dyed, not adding reference 
DNA, running overtime, etc. 
Incorrect electrophoresis 
and immediate repetition 
No effect Technician error 
Technician validation of 
electrophoresis result 
1 2 1 2 Training 
Electrophoresis 
Sample identity and 
electrophoresis gel photo do not 
correspond to each other 
Lack of traceability of QC 
result 
No effect 
Technician error 
(manual tracking in 
excel) 
Technician inspection 1 2 4 8 
Register electrophoresis the 
sample identity and position 
in notebook or excel 
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4.4.8 Analytical Phase: Robot 1 Normalization and Quantification 
Table 13. FMEA of Robot 1 
Robot 1 Normalization and Quantification 
Step of 
Process 
Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RL RPN Action Recommended 
Automatic 
normalization 
Robot 1 does not work 
Normalization not 
performed (manual 
normalization) 
Delayed 
result  
Hardware 
malfunction 
Technician observation 4 3 1 12 12 
Technician training of 
immediate recovery 
Automatic 
normalization 
Accident occurs during Robot 1 
processing (e.g. arm crashing, 
pipetting problems, quantification 
error, etc.) 
Incorrect 
normalization 
No result 
Hardware 
malfunction 
Technician observation;  
Robot 1 alert and technician 
inspection of error log;  
PCR QC 
4 2 1 8 8 
Technician watches Robot 
operation; check error log 
always 
Normalization 
programming 
Incorrect processing protocol (script) 
is selected 
Normalization 
failure (immediate 
repetition) 
No effect Technician error 
Technician observation (Robot 
1 alert and cannot proceed) 
1 1 1 1 1 
Set internal logic sequence 
of the scripts: alert when 
skip previous steps 
Normalization 
programming 
Incorrect parameters are inputted in 
Robot 1 (e.g. position of starting 2D 
tubes, position of starting dilution 
plate, sex PCR Y/N) 
Sample wasted (re-
extraction if primary 
sample is left) 
No result Technician error 
Technician observation (Robot 
works with warning or cannot 
proceed) 
4 3 2 12 24 
Reset "position of 2D tube" 
as 0 (to clean used 2D tubes 
and reorganize from 0) 
Reagent 
loading 
Incorrect reagents, primers are 
loaded, or placed in incorrect 
positions 
No amplified 
products of sex PCR 
QC (immediate 
repetition) 
No effect Technician error QIAxcel QC 1 2 1 2 2 
Clearly labelling of position 
and corresponding reagents 
Aliquot 
loading 
Necessary secondary tubes are not 
loaded to receive aliquot DNA sample 
Test not performed 
(no aliquots) 
No result Technician error 
Technician inspection of 
additional secondary labels; 
Core BM clients ask for sample 
4 3 1 12 12 
Robot 1 checks with SIL the 
number of extra aliquots 
and alert 
Sample 
registration 
Incorrect barcode number of sample 
is entered manually (request#) and is 
linked to a 2D tube 
Sample incorrectly 
identified 
Misleading 
result 
Technician error Undetectable 5 2 5 10 50 
Technician double check 
after scanning or manual 
introduction 
Manual 
decapping 
Less 2D tubes are decapped than 
needed 
Sample wasted (re-
extraction if primary 
sample is left) 
No result 
SIL bad mapping; 
Network error;  
Technician error 
Technician observation (Robot 
works with warning or cannot 
proceed) 
4 2 1 8 8 No 
Robot data 
output 
No data is transferred to SIL after 
normalization completed 
No traceability in SIL No effect Network error 
Technician inspection when 
necessary 
1 1 1 1 1 No 
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4.4.9 Analytical Phase: Robot 2 PCR Assembly and PCR 
Table 14. FMEA of Robot 2 
Robot 2 PCR Assembly & PCR 
Step of 
Process 
Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RL RPN Action Recommended 
Automatic 
assembly 
Robot 2 does not work 
PCR reaction cannot be 
assembled 
automatically (manual 
assembly) 
Delayed result  Hardware malfunction Technician observation 4 2 1 8 8 
Technician training of 
immediate recovery 
Automatic 
assembly 
Accident occurs during Robot 2 
processing (e.g. arm crashing, 
pipetting problems, etc.) 
Incorrect PCR assembly No result Hardware malfunction 
Technician observation;  
Robot 2 alert and 
technician inspection of 
error log; Technician 
validation of sequencing 
quality 
4 2 1 8 8 
Technician watches 
Robot operation; check 
error log always 
Reagent 
loading 
Incorrect or inappropriate 
concentration of  reagents is 
loaded (Amplitaq, water), or place 
reagents in incorrect positions 
Incorrect PCR assembly 
and always sufficient 
DNA sample for 
immediate repetition 
No effect Technician error QIAxcel QC 1 2 1 2 2 
Clearly labelling of 
position and 
corresponding reagents 
Sample 
registration 
Not all 2D tubes in one plate are 
scanned and read into sample 
tracking database 
Sample left in "WAIT" 
rack and no PCR 
assembly performed 
Delayed result  Hardware malfunction 
Technician inspection of 
SIL worklist 
4 2 3 8 24 
Robot tells the number 
of 2D tubes after reading 
and technician checks 
SIL data input 
Input information from SIL (e.g. 
exons) is delayed 
Delayed PCR Delayed result  
Physician entry delayed;  
Network error 
Technician inspection of 
sample list in database 
4 3 1 12 12 
Original request contains 
all information necessary 
(test, gene, exon…) 
SIL data input 
Information from SIL (e.g. exons) is 
incorrect 
1-Inappropriate exon 
amplified 
2-No primer is found 
No result Physician entry error 
Robot 2 alert;  
Physician validation of 
sequencing result 
4 3 1 12 12 
Doctor training of 
ordering tests 
Primer 
selection 
Primer selected (from Cytomat) for 
exon amplification is incorrect 
Inappropriate exon 
amplified 
No result 
Technician error (transfer 
error when diluting primer 
into 2D tubes; primer 
database registration 
error/ not updated timely/ 
changed by error, etc.) 
Physician validation of 
sequencing result 
4 2 1 8 8 
Scan and check again 
before return to 
Cytomat; Technician 
check primer list 
regularly 
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Table 14. FMEA of Robot 2 (Continued) 
Robot 2 PCR Assembly & PCR 
Step of 
Process 
Failure Mode Immediate Effects End effects Causes 
Methods of 
Detection 
S P D RL RPN Action Recommended 
Primer 
selection 
Primer is not found in Cytomat or 
primer is insufficient 
Short delayed process No effect 
Technician error (old 
primer insufficient or 
changed; new primer 
not prepared); Primer 
database error 
Robot 2 alert and 
technician 
inspection of 
error log 
1 2 1 2 2 
Cytomat checks in advance 
according to SIL request 
2D tube 
distribution 
2D tube is assigned to "END" 
incorrectly (according to SIL) 
1-Test not performed 
(request closed or 
canceled) 
2-2D tube DNA aliquot 
discarded 
No result  
Network error; 
Request is closed by 
physician incorrectly 
Undetectable 4 2 5 8 40 No 
Automatic 
assembly 
One DNA sample is insufficient for 
all multiple amplifications 
requested (100ul DNA in one 2D 
tube is sufficient for 50 
amplifications) 
No more DNA sample 
for repetition PCR 
assembly 
No result  
Insufficient sample 
received; DNA 
Extraction error 
PCR QC 4 2 1 8 8 No 
Robot data 
output 
No data is transferred to SIL after 
assembly completed 
No traceability in SIL No effect Network error 
Technician 
inspection when 
necessary 
1 1 1 1 1 No 
Manual PCR 
assembly 
Incorrect protocol or inappropriate 
volume or concentration of kit/ 
reagent/ primer is used 
1-Inappropriate exon 
amplified 
2-PCR assembly failure 
and not always 
sufficient DNA for 
repetition 
3-Short delayed PCR and 
immediate repetition 
No result Technician error 
QIAxcel QC;  
Physician 
validation of 
sequencing 
4 2 1 8 8 No 
Manual PCR 
assembly 
Sample is transferred to incorrect 
position in the PCR plate (when 
there are multiple samples in a 
batch) 
Sample incorrectly 
identified 
Misleading 
result 
Technician error 
(sample transfer; bad 
labelling) 
Undetectable 5 2 5 10 50 
Use a notebook (not excel) to 
register the position of samples, 
always check the notebook 
during the manual assembly. 
Mark the rack or plate with a 
starting position 
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Table 14. FMEA of Robot 2 (Continued) 
PCR 
Step of 
Process 
Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RL RPN Action Recommended 
PCR 
Incorrect processing program 
is selected 
PCR failure and immediate 
repetition 
No effect Technician error QIAxcel QC 1 2 1 2 2 No 
PCR PCR works with error 
PCR failure and immediate 
repetition 
No effect 
Hardware 
malfunction 
QIAxcel QC 1 1 1 1 1 
Regular calibration and 
maintenance 
PCR 
Manually prepared plate or 
samples are not identifiable 
PCR result not identifiable and 
immediate repetition 
No effect Technician error Technician inspection 1 2 1 2 2 
Put a notebook beside 
and register each plate 
and start time 
PCR Plate is not sealed 
PCR failure and immediate 
repetition 
No effect Technician error 
Technician inspection; 
QIAxcel QC 
1 1 1 1 1 No 
PCR PCR is not done Delayed test Delayed result Technician error 
Technician inspection; 
Core BM clients ask 
for result 
4 1 2 4 8 
Require traceability for 
each step 
QIAxcel QC 
QC result is mis-matched with 
another sample 
Inappropriate sample is proceeded 
when no amplified product and 
repetition after sequencing result 
obtained (if sample sufficient ) 
1-No result 
2-Delayed result  
Technician error 
(sample transfer) 
Technician validation 
of sequencing quality 
4 1 1 4 4 No 
QIAxcel QC 
Negative control is 
contaminated (e.g. by 
microorganisms, samples, 
unexpected substances, etc.) 
1-Contaminated sample is 
proceeded 
2-Inappropriate sample is 
proceeded and repetition after 
sequencing result obtained (if 
sample sufficient ) 
1-No result 
2-Delayed result  
Technician error 
Technician validation 
of sequencing quality 
4 2 2 8 16 No 
QIAxcel QC QIAxel does not work 
Manual electrophoresis QC 
performed 
No effect 
Hardware 
malfunction 
Technician 
observation 
1 2 1 2 2 No 
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4.4.10 Analytical Phase: Robot 3 PCR Purification 
Table 15. FMEA of Robot 3 
Robot 3 PCR Purification 
Step of 
Process 
Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RL RPN Action Recommended 
Automatic 
Purification 
Robot 3 does not work 
Manual purification 
performed 
No effect Hardware malfunction Technician inspection 1 2 1 2 2 
Technician training of 
immediate recovery 
Automatic 
Purification 
Accident occurs during Robot 3 
processing (e.g. arm crashing, 
pipetting problems, etc.) 
Incorrect purification No result Hardware malfunction 
Technician observation;  
Robot 3 alert and 
technician inspection of 
error log;  
Technician validation of 
sequencing quality;  
Physician validation of 
sequencing result 
4 2 1 8 8 
Technician watches Robot 
operation; check error log 
always 
Sample 
registration 
PCR plate loaded for 
purification does not 
correspond to the plate ID 
introduced (manually entered 
or scanned) in Robot 3 
Sequencing report 
incorrectly assigned to the 
samples in another plate 
(sequencing result is 
correct) 
No effect 
Technician error; 
Network error; 
scanner error 
Technician validation of 
sequencing report 
1 1 1 1 1 Double check 
Reagent 
loading 
Incorrect purification reagents 
(Exostar, Bigdye, M13, 
Formamide, etc.) is loaded, or 
placed in incorrect positions 
1-Sequencing failure and 
immediate repetition from 
PCR amplified products 
(always sufficient sample) 
2-Poor sequencing quality 
No effect Technician error 
Technician validation of 
sequencing quality;  
Physician validation of 
sequencing result 
1 2 1 2 2 
Clearly labelling of position and 
corresponding reagents 
Purification 
programming 
Incorrect processing protocol 
(script of Exostar, Bigdye, 
Formamide) is selected 
Robot cannot work No effect Technician error 
Technician observation; 
Robot alert and 
technician inspection of 
error log 
1 2 1 2 2 
Set internal logic sequence of 
the scripts: alert when skip 
previous steps; traceability of 
PCR plate in Robot database 
Purification 
programming 
Not all steps of purification is 
completed (skip 1 or 2 steps, 
e.g. not add formamide), or 
the script sequence is incorrect 
1-Sequencing failure and 
immediate repetition from 
PCR amplified products 
(always sufficient sample) 
2-Poor sequencing quality 
Acceptable 
result with 
minor defect 
Technician error 
Technician validation of 
sequencing quality;  
Physician validation of 
sequencing result 
2 2 1 4 4 
Set internal logic sequence of 
the scripts: alert when skip 
previous steps; traceability of 
PCR plate in Robot database 
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Table 15. FMEA of Robot 3 (Continued) 
Robot 3 PCR Purification 
Step of 
Process 
Failure Mode Immediate Effects End effects Causes 
Methods of 
Detection 
S P D RL RPN Action Recommended 
Purification 
programming 
Number of samples entered is more than 
actual number (>48 use 2 plates to 
assemble sequencing reaction; <48 use 1 
plate is enough) 
No effect No effect Technician error 
Technician 
observation 
1 1 1 1 1 No 
Purification 
programming 
Number of samples entered is less than 
actual number (E.g. enter 48 for 49 
samples, Robot uses 1 plate to assemble 
sequencing reaction, so sample #49 is 
mixed with sample#1; or formamide is 
not done for some samples) 
1-Sample cross-
contaminated 
2-Sample assembly not 
completed 
No result Technician error 
Technician 
validation of 
sequencing quality;  
Physician validation 
of sequencing result 
4 2 2 8 16 
Number of samples can be 
known from the database of 
R2 (when PCR plate ID is 
entered) and compare with 
manual entry? Modification 
requires confirmation. 
Sample 
collection 
The final sample receiving plate is not 
placed under EdgeBio to collect the 
sample 
Sample wasted and 
immediate repetition from 
PCR amplified products 
No effect Technician error 
Technician 
observation 
1 1 1 1 1 No 
Centrifuge 
Final sample receiving plate is not 
centrifuged 
1-Sample wasted and 
immediate repetition from 
PCR amplified products 
2-No sample in the 
receiving plate and 
centrifuge again 
No effect Technician error 
Technician 
observation 
1 1 1 1 1 No 
Robot data 
output 
No data is transferred to SIL after 
purification completed 
Lack of traceability of 
process 
No effect Network error 
Technician 
inspection when 
necessary 
1 1 1 1 1 No 
 
 83 
 
4.4.11 Analytical Phase: Sanger Sequencing and Fragment Analysis 
Table 16. FMEA of Sanger SEQ and AF 
Sanger Sequencing & Fragment Analysis 
Step of Process Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RL RPN 
Action 
Recommended 
Sequencing & 
Fragment 
Analysis 
All sequencers do not work Delayed test Delayed result  Hardware malfunction Technician observation 4 1 1 4 4 
Technician training 
of immediate 
recovery 
External sample 
inspection 
DNA sample preparation by external 
clients does not meet the sequencing 
criteria (e.g. contaminated, low 
concentration or purity) 
Test performed with invalid 
sample 
1-No result 
2-Delayed result 
Core BM clients 
preparation error 
Technician validation of 
sequencing quality;  
Physician validation of 
sequencing result 
4 4 2 16 32 No 
External sample 
registration 
Sample tube/plate ID or quantity received 
do not correspond to the request (IMP-
204 in SIL) 
Delayed test (confirmation or 
re-extraction is needed) 
Delayed result  
Core BM clients error 
(handwritten sample 
name not identifiable; 
transportation, request 
programming error) 
Technician inspection 4 2 1 8 8 No 
External sample 
registration 
Sample tube or plate received is not 
identified or poorly identified 
Delayed test (confirmation or 
re-extraction is needed) 
Delayed result  
Core BM clients error 
(handwritten sample 
name not identifiable or 
no label) 
Technician inspection 4 2 1 8 8 
Unify plate ID 
corresponding to 
each PCR plate in 
Robot 2 
External sample 
transfer 
More than 1 sample is transferred to the 
same position in a plate 
1-Test performed with 
invalid sample 
2-Repetition after physician 
validation 
1-No result 
2-Delayed result 
Technician error 
(overlapped 
programming, sample 
transfer) 
Technician validation of 
sequencing quality;  
Physician validation of 
sequencing result 
4 2 2 8 16 No 
External sample 
transfer 
No sample is transferred to a 
programmed position in a plate 
1-Test not performed 
2-Repetition after physician 
validation 
1-No result 
2-Delayed result 
Technician error 
(sample transfer) 
Technician validation of 
sequencing quality 
4 2 1 8 8 No 
External sample 
transfer 
Sample is transferred to erroneous 
position (not consistent with the 
programmed position) 
Sample incorrectly identified 
Misleading 
result 
Technician error 
(sample transfer) 
Undetectable 5 2 5 10 50 No 
External sample 
transfer 
Insufficient volume is transferred to the 
sequencing plate 
Sequencing failure 
and immediate repetition 
from sample transfer (if 
sample sufficient) 
No result 
Technician error 
(sample transfer) 
Technician validation of 
sequencing quality 
4 2 1 8 8 No 
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Table 16. FMEA of Sanger SEQ and AF (Continued) 
Sanger Sequencing & Fragment Analysis 
Step of 
Process 
Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RL RPN Action Recommended 
Worklist 
input 
Worklist imported to a specific 
sequencer is not readable 
Immediate correction of 
template or format 
No effect 
Technician error 
(inappropriate template is 
used; incorrect entry or 
modification);  
Robot 3 worklist output 
error 
Technician observation 1 1 1 1 1 
Modification to auto 
worklist is not 
recommended. Check 
sample numbers with 
worklist 
Worklist 
input 
Sequencer proceeds with 
incorrect worklist (sample ID, 
position, etc.) 
Result incorrectly assigned 
Misleading 
result 
Technician error (manual 
entry or modification error);  
Robot 3 worklist output 
error;  
Core BM clients worklist 
error 
Doctors or Core BM 
clients doubt of result 
(e.g. a "recessive 
autosomal disease" is 
only possible when 
phenylketonuria?) 
5 2 4 10 40 
Modification not 
recommended. 
Double check 
Worklist 
input 
Sequencer proceeds with 
incomplete worklist 
Test not performed for 
some samples and 
immediate repetition of 
sequencing 
No effect 
Technician error (manual 
entry or modification error);  
Robot 3 worklist output 
error;  
Client worklist 
Technician validation of 
sequencing report 
1 2 1 2 2 
Modification to auto 
worklist is not 
recommended. Check 
sample numbers with 
worklist 
Sequencing 
programming 
Incorrect sample position is 
selected to perform 
sequencing 
Sequencing disorder and 
immediate repetition 
No effect Technician error 
Technician validation of 
sequencing report 
1 2 1 2 2 No 
Sequencing 
programming 
Incorrect assay/ script is 
selected 
1-Sequencing failure and 
immediate repetition if 
sample sufficient 
2-Poor sequencing quality 
for physician validation 
No result Technician error 
Technician validation of 
sequencing quality 
4 2 1 8 8 No 
Sequencing & 
Fragment 
Analysis 
Negative quality control is not 
done or inappropriately 
interpreted (e.g. contaminated 
blank control is not detected) 
Poor sequencing quality 
for physician validation 
No result 
Technician error;  
Lack of training 
Physician validation of 
sequencing result 
4 1 2 4 8 No 
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Table 16. FMEA of Sanger SEQ and AF (Continued) 
Sanger Sequencing & Fragment Analysis 
Step of 
Process 
Failure Mode Immediate Effects End effects Causes Methods of Detection S P D RL RPN 
Action 
Recommended 
Sequencing & 
Fragment 
Analysis 
Accident occurs during 
sequencing process 
1-Sequencing failure and 
immediate repetition if sample 
sufficient 
2-Poor sequencing quality for 
physician validation 
No result Hardware error 
Technician observation; 
Technician validation of 
sequencing quality;  
Physician validation of 
sequencing result 
4 2 1 8 8 No 
Sequencing & 
Fragment 
Analysis 
Sequencing result is sent to 
incorrect physician 
1-Delayed physician validation 
2-Short delayed process 
Delayed result  
Technician error 
(manually sent; Select 
incorrect naming rule/ 
results folder);  
Sequencer automatic 
distribution error 
Physicians ask for result 4 2 2 8 16 No 
Sequencing & 
Fragment 
Analysis 
Result is not sent out 
1-Delayed physician validation 
2-Short delayed process 
Delayed result  
Technician error; 
Sequencer automatic 
distribution error 
Technician inspection of 
pending report; 
Physicians ask for result 
4 2 2 8 16 No 
Sequencing & 
Fragment 
Analysis 
Repetition 
Sample after addition of 
formamide for a long time is 
used for repetition 
1-Sequencing failure and 
immediate repetition if sample 
sufficient 
2-Poor sequencing quality for 
physician validation 
No result Technician error 
Technician validation of 
sequencing quality 
4 2 1 8 8 No 
4.4.12 Post-analytical Phase: Physician Validation and Sample Archiving 
Table 17. FMEA of Physician Validation and Sample Archiving (Post-analytical) 
Post-analytical 
Step of 
Process 
Failure Mode Immediate Effects End effects Causes 
Methods of 
Detection 
S P D RL RPN 
Action 
Recommended 
Physician 
validation 
Sequencing result validation is incorrect Incorrect interpretation 
Misleading 
result 
Physician 
error 
Doctors doubt 
of result 
5 1 4 5 20 Double check 
Physician 
validation 
Validation report is assigned to another patient 
in SIL 
Report incorrectly identified 
Misleading 
result 
Physician 
error 
Doctors doubt 
of result 
5 1 4 5 20 
SIL automatically 
assign report 
Sample 
archiving 
Sample is not archived appropriately (e.g. 
discarded or stored in incorrect condition, etc.) 
1-No sample for repetition 
2-Poor quality of sample for repetition 
Patient 
discomfort 
Technician 
error 
Undetectable 2 1 5 2 10 No 
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4.5 Results Summary and Discussions 
4.5.1 FMEA Results and Discussions 
216 Risks were identified for all the phases and departments. Among them 50% were from 
pre-analytical phase, 47% were from analytical phase (Core BM), and only 7% were from 
post-analytical phase. Table 18 summarizes the risks distribution across departments.  
Table 18. FMEA Summary 
  Pre-analytical Analytical Post-analytical  
Risk  Reception CE RM Secretary Core BM Secretary Sum 
High 2 0 0 4 0 6 (3%) 
Medium 3 6 3 3 0 15 (7%) 
Minor 22 22 5 22 2 73 (34%) 
Low 22 19 4 72 5 122 (56%) 
Sum 49 47 12 101 7 216 
  108 (50%) 101 (47%) 7 (3%) 216 (100%) 
21 risks were ranked as high or medium to be treated with priority, which mainly focused 
on sample quality and manual procedures. Sample quality is crucial for a good result. To 
control the necessary storage condition, the correct extraction procedure, timely and secure 
transportation before or during the analysis are the actions to ensure sample quality. Manual 
procedures of identifying and labelling patients and samples in both pre-analytical and 
analytical phases are the weakest links in overall workflow: they bear the catastrophic 
effects and most of them are undetectable. Especially when processing the samples by 
batch, the technicians can easily cross the sample identity thus the result would be totally 
incorrect and misleading. Since the Core BM is equipped with 4 robots handling all the 
samples and procedures, to avoid as much as possible the manual procedures and to 
establish a smarter labelling system with clear traceability are the most important actions 
to be taken.  
Actions were proposed to treat as many as possible the identified risks. All the actions 
regarding the 21 high and medium risks were recommended to the management team for 
immediate implementation. Considering the cost-effective requirements, there are some 
common actions for different risks, which will reduce significantly the overall RPN, such 
as: 
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1) Program the informatics system in a smarter way to avoid human errors in all the TTP 
processes:  
a. The labels in SIL and the request forms in SAP can be designed more user-
friendly, so that they have all the necessary information. E.g.: to list the total 
number of labels on each label and to list the total number of sample tubes on 
the request form will make the laboratory staff to read more easily.  
b. Gradually popularize the use of SIL interface among external clients. This will 
reduce the probability of managing manual requests of various forms, which 
bears many high risks.  
c. Improve the robots’ capability of information exchange with SIL, so as to avoid 
manual entry of sample numbers or other information during the automatic 
processes.  
2) Patient and client communication about the sample requirements is the key to ensure 
sample quality and quantity. To give the patient necessary instructions before taking 
samples and to inform client of the acceptable sample criteria will largely reduce the 
probability of receiving insufficient or inadequate samples.  
3) Clearly label and group the samples is critical to ensure all the samples are managed in 
an expected way and not cross-mixed.  
4) For all the laboratory technicians, the training of immediate recovery of the equipments 
or robots they operate is the most effective way to avoid sample waste and delay of 
result. 
4.5.2 Methodology Discussions 
This risk assessment study lasted for 6 months and is still ongoing in terms of risk treatment 
and continuous monitoring. Compared to previous studies, it covered full TTP scope and 
thus seemed time-consuming. 2 months were spent in observing the laboratory processes. 
In risk management, it is an issue that the task performer is not familiar with the processes. 
To study them is time-consuming and heavy work which however is the premise of better 
assessment and management. Sometimes the study cannot be comprehensive due to time 
limitation, which could impact the quality of the risk assessment. More efficiently and 
effectively, the risk identification part can be performed by an expert who already possesses 
the knowledge of a certain process. So it is a good approach to train the experts to have a 
basic risk-based mindset to contribute in risk management and quality management. In such 
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context, the quality manager should only be a facilitator of the team and provide expertise 
in methodologies. In a larger scope, everyone who works in a clinical laboratory should 
bear the quality and risk management in mind, so as to contribute in their daily work. 
Risk assessment is subjective and may vary if performed by different teams [43]. The 
scoring criteria, the RPN matrix, the definition of each terminology, etc. none of them has 
an existing standard or reference. To be practical and meet the needs of the organization is 
the only and ultimate principle. In order to achieve the effective goal, an experienced and 
cross-functional team is the key of success. In this study, the most challenging part was to 
define and apply the criteria of S, P and D. In multiple rounds of reviews, the criteria were 
modified several times and finally the team reached to an agreement.  
Previous studies applied FMEA to simple processes and the criteria of S, P and D are 
simple. While performing a large scope risk assessment such as TTP scope, another 
approach could be suggested: to define customized criteria for different processes. E.g. in 
this study, for pre-analytical area, P was defined as the occurrence per patient, while for 
analytical phase, it was defined per sample. Similarly, it would also be possible to define 
different criteria S based on the outcome of each general process. This may result in more 
work but the assessment will be more precise and effective.  
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5 CONCLUSIONS 
From the risk assessment study we have performed for the clinical laboratory in a TTP 
scope, we conclude that: 
1) It is clear that the laboratory errors and delays can potentially have huge impact on 
patient safety by means of delivering laboratory results as diagnostic references. Among 
the 21 prioritized risks, 19 bear the severity score 4 or 5. Which means these risks of 
higher probability and lower detectability can result in critical or catastrophic effects on 
patient safety. The most critical and weakest link in TTP is the manual sample 
identification procedures, in which samples are labeled or identified manually. It is 
necessary to avoid as much as possible the manual processes and to create a smarter 
sample labelling system.  
2) Risk assessment is a powerful tool to avoid or mitigate the errors and delays in a clinical 
laboratory. It is an important tool in the laboratory quality management system that 
ensures the reliability of test results and contributes to assure patient safety. It is the 
foundamental step of the dynamic risk management system. The improvement is 
expected after the implementation of the proposed actions, and the risks may vary 
during continuous improvement, which should be monitored and reviewed regularly. 
3) FMEA is successfully applied to perform a risk assessment for the clinical laboratory 
TTP processes. It enables to identify potential process failures before they occur and 
helps to prioritize risks in the weakest links, where improvement actions are needed. 
The methodology can be customized according to different context to meet different 
needs.  
4) To our knowledge, this is the first study in Europe that applied FMEA in a hospital 
clinical laboratory in the TTP scope, i.e. pre-analytical, analytical and post-analytical 
phases of Core BM. It has laid the foundation of the risk management system in the 
laboratory, and allows the future improvement from both detailed steps and general 
scope.   
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